documents incorporated reference specified portions registrants definitive proxy statement filed commission pursuant regulation connection annual meeting incorporated reference part iii report based closing price per share excludes shares registrants common stock held executive officers directors stockholders whose ownership exceeds common stock outstanding june exclusion shares construed indicate person possesses power direct indirect direct cause direction management policies registrant person controlled common control registrant gilead sciences inc annual report table contents part item business item properties item legal proceedings item submission matters vote security holders part ii item market registrants common stock related stockholder matters item selected financial data item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data item changes disagreements accountants accounting financial disclosure item controls procedures part iii item directors executive officers registrant item executive compensation item security ownership certain beneficial owners management item certain relationships related transactions item principal accountant fees services part iv item exhibits financial statement schedules reports form k signatures rights various trademarks copyrights trade names used business including following gilead gilead sciences hepsera leaf shield design leaf shield design bw liver design tablet design bw tablet design color viread vistide daunoxome ambisome emtriva tamiflu registered trademark belonging hoffmannla roche report also includes trademarks service marks trade names companies part item business forwardlooking statements risk factors report includes forwardlooking statements particular statements expectations beliefs plans objectives assumptions future events performance contained incorporated reference report based forwardlooking statements current expectations future events believe expectations reasonable forwardlooking statements inherently subject risks uncertainties many beyond control actual results may differ materially suggested forwardlooking statements various reasons including discussed report heading risk factors affect gilead given risks uncertainties cautioned place undue reliance forwardlooking statements forwardlooking statements included report made date hereof undertake specifically decline obligation update statements publicly announce results revisions statements reflect future events developments used report unless otherwise indicated us refers gilead subsidiaries overview gilead sciences inc biopharmaceutical company discovers develops commercializes therapeutics advance care patients suffering lifethreatening diseases worldwide six products currently marketed us also marketed countries worldwide research clinical programs focused antiinfectives including antivirals antifungals endeavor grow existing portfolio products proprietary clinical development programs internal discovery programs active product acquisition inlicensing strategy worldwide headquarters foster city california european headquarters paris france incorporated delaware june january completed acquisition net assets triangle pharmaceuticals inc triangle expand antiviral pipeline aggregate purchase price million including cash paid outstanding stock fair value stock options assumed estimated direct transaction costs employee related costs approximately million purchase price recorded inprocess research development expense triangle developed drug candidates antiviral area particular focus potential therapies hiv including aids hepatitis b virus triangles portfolio consisted several drug candidates clinical trials including emtrivatm emtricitabine treatment hiv infection emtricitabine treatment chronic hepatitis b amdoxovir treatment hiv infection clevudine treatment chronic hepatitis b july us food drug administration fda approved marketing emtriva treatment hiv october european commission granted marketing authorisation emtriva fifteen member states european union subsequently returned rights amdoxovir clevudine licensors commercial interest compounds products viread approved sale sold us us commercial team use combination antiretroviral agents treatment hiv infection viread also sold internationally international commercial teams including european union australia emtriva approved sale sold us us commercial team use combination antiretroviral agents treatment hiv infection adults emtriva also sold european union international commercial teams currently developing fixeddose combination viread emtriva ambisome approved sale sold countries treatment lifethreatening fungal infections countries prevention infections market ambisome major countries europe copromote ambisome us fujisawa healthcare inc fujisawa hepsera approved sale sold us us commercial team treatment chronic hepatitis b hepsera received marketing approval european union march launched countries european union additional launches countries european union parts world expected occur tamiflu approved sale sold corporate partner hoffmannla roche roche countries including us european union prevention treatment influenza japan approved treatment influenza vistide approved sale sold us us commercial team gileads exus partner pfizer inc pfizer formerly pharmacia corporation countries treatment cytomegalovirus cmv retinitis patients aids daunoxome approved sale sold countries treatment aidsrelated kaposis sarcoma sold us us commercial team independent distributors abroad december decided discontinue selling product earned revenues million sales royalties products amount sales viread generated aggregate product sales royalty revenues million total revenues sales ambisome generated aggregate product sales royalty revenues million total revenues earned revenues sales royalties products us million million million outside us earned revenues sales royalties products million million million viread tenofovir disoproxil fumarate viread oral formulation nucleotide analogue reverse transcriptase inhibitor tenofovir df dosed day part combination therapy treat hiv infection adults drug works blocking reverse transcriptase enzyme involved replication hiv sell viread us us commercial team major european countries european commercial team see commercial operations fda approved viread marketing us october european agency evaluation medicinal products emea granted similar approval european union february may emea expanded indication viread include use antiretroviralnave hiv infected patients august fda similarly expanded indication viread us us viread approved use combination antiretroviral agents treatment hiv infection indication based analyses plasma hiv rna levels cd cell counts controlled dose ranging study viread weeks duration study placebocontrolled study viread weeks duration study studies conducted treatmentexperienced adults evidence hiv viral replication despite ongoing antiretroviral therapy expanded indication based week results ongoing threeyear randomized doubleblind clinical trial study designed compare efficacy safety combination treatment regimen viread lamivudine tc efavirenz combination treatment regimen stavudine dt lamivudine efavirenz antiretroviralnave patients hiv infection february reported week data study data study demonstrates treatmentnave patients received viread experienced substantially less lipodystrophy lower elevations fasting cholesterol triglyceride levels well improved levels limb fat weight gain achieving similar reductions hiv viral load increases cd cell counts compared received stavudine common adverse events reported included viral infection diarrhea headache occurred similar frequency two study arms discontinuation rate approximately percent patients viread arm percent patients stavudine arm week data supplements week results study submitted fda support use viread one major challenges treating hivinfected patients drug resistance many existing therapies treating hiv infection aids rely similarlydesigned drug processes patients developed resistance one drug often develop resistance drugs within class believe viread approved regulatory authorities offers advantages approved hiv treatments available data shown patients developed resistance viread viread effective treating patients developed resistance therapies certain however resistance data may obtain upon completion phase clinical trials show similar resistance characteristics week data study data obtained limited phase clinical trials another major concern hiv treatment convenience dosing combination therapies positive impact require hivinfected patients take numerous drugs drugs require multiple doses every day many timing dietary restrictions results inconvenience patients also contributes patients missing doses adhering therapy viread approved administered oncedaily oral pill schedule may appealing hivinfected patients physicians hiv competitive landscape becoming crowded complicated treatment trends continue evolve twentytwo branded antihiv drugs currently sold us many others advanced stages clinical development see competition exclusive worldwide license patent rights related technology viread institute organic chemistry biochemistry part academy sciences czech republic rega stichting vzw together iocbrega obligated pay percentage net revenues sales viread us european union countries product approved patent protection iocbrega see academic consulting relationshipsiocbrega emtriva emtricitabine emtriva oral formulation nucleoside analogue reverse transcriptase inhibitor dosed day part combination therapy treat hiv infection adults sell emtriva us us commercial team major european countries european commercial team see commercial operations fda approved emtriva marketing us treatment hiv july european commission granted marketing authorisation emtriva fifteen member states european union october emtriva antiviral agent hiv strains obtained geographically diverse set hivinfected patients laboratory studies shown emtriva shares crossresistance patterns lamivudine common resistance mutation two agents also reverses resistance hiv azt cases four phase clinical studies emtriva completed one collaboration agence nationale de recherches sur le sida anrs france one studies study ftc compared emtriva mg onceaday stavudine mg twiceaday combination didanosine mg onceaday efavirenz mg onceaday patients without previous antiretroviral therapy july independent data safety monitoring board dsmb established provide oversight study recommended emtriva offered patients enrolled study interim results evaluated studys dsmb showed emtriva arm statistically superior stavudine arm primary secondary endpoints safety efficacy eightyseven percent patients onceaday emtriva arm persistent virologic response six months compared twicedaily stavudine arm patients emtriva arm also significant improvements immunologic function view compelling difference favor emtriva arm dsmb recommended study amended patients given option switch openlabel emtriva continue blinded therapy last randomized patient completed week october final analysis study confirmed superior efficacy safety emtriva compared stavudine combination didanosine efavirenz exclusive worldwide license patent rights related technology emtriva emory university see academic consulting relationshipsemory university university georgia research foundation ambisome amphotericin b liposome injection ambisome proprietary liposomal formulation amphotericin b amphotericin b powerful antifungal agent known ability treat serious invasive fungal infections caused various fungal species infections generally life threatening particularly patients depressed immune systems due aggressive chemotherapy regimens stem cell organ transplant hiv infection amphotericin b treatment also serious side effects includingkidney toxicity studies show however delivering amphotericin b proprietary liposomal formulation ambisome reduces rate severity kidney toxicity injectionrelated reactions allows patients receive higher doses amphotericin b ambisome approved sale countries including us european union rest europe australia canada several countries middle east latin america asia countries ambisome approved including us authorized promote ambisome empirical treatment fungal infections ie treatment patients strong suspicion without definite confirmation exists potentially lifethreatening invasive fungal infection remaining countries ambisome approved sale approved use either firstline treatment serious invasive fungal infection secondline treatment conventional amphotericin b therapy fails conventional amphotericin b tolerated finally ambisome approved number countries various indications example cryptococcal meningitis aids patients prophylaxis liver transplant patients visceral leishmaniasis us copromote ambisome fujisawa us commercial team agreement fujisawa entitles us percentage revenues generated sales provides fujisawa purchases ambisome us manufacturing cost see collaborative relationshipsfujisawa major european countries australia sell ambisome international commercial teams certain countries sell ambisome independent distributors revenues ambisome europe expect case foreseeable future licensed commercial rights ambisome japan sumitomo pharmaceuticals co ltd sumitomo exchange royalties generated activities however ambisome yet approved sale japan ambisome faces strong competition several current competitors expected competitors whose treatments late stage clinical trials see competition competition current expected competitors likely erode revenues receive sales ambisome hepsera adefovir dipivoxil hepsera oral formulation nucleotide analogue hbv dna polymerase inhibitor adefovir dipivoxil dosed day treat chronic hepatitis b hepatitis b caused highly contagious hepatitis b virus hbv cause acute liver failure patients develop chronic hepatitis b infection many years lead complications cirrhosis liver cancer liver failure approximately patients result death according recent estimates world health organization centers disease control million people worldwide million people us chronic hepatitis b one million deaths attributable chronic hepatitis b worldwide year one ten leading causes death worldwide hepsera disables hbv interfering activity enzyme known hbv polymerase necessary virus replicate applications us european union marketing authorizations included data two separate phase clinical trials designed evaluate safety efficacy hepsera mg dosage treating patients hepatitis b virus phase trials designed randomized doubleblind placebocontrolled studies clinical sites us canada europe australia southeast asia study evaluated hepsera treating patients test positive hbv e antigen common type hepatitis b us trial study evaluated hepsera treating patients type hepatitis b known precore mutant hepatitis b common southeast asian mediterranean countries weeks adefovirassociated resistance mutations identified hepatitis b patients treated clinical trials suggests development resistance hepsera hepatitis b patients may delayed infrequent consequently believe hepseras resistance profile could make important drug treating chronic hepatitis b certain however resistance data may obtain continuing phase clinical trials hepsera continue show resistance characteristics hepsera approved sale us treatment chronic hepatitis b adults evidence active viral replication either evidence persistent elevations serum aminotransferases alt ast histologically active liver disease us commercial team sells hepsera us march applied approval emea hepsera treatment chronic hepatitis b european union approval emea recommended committee proprietary medicinal products cpmp november received march plan sell hepsera major european union countries european commercial team vaccine available prevent transmission hbv effective people already become chronically infected hbv expect vaccine becomes widely available incidence new hepatitis b infections decrease however even advances prevention hepatitis b individuals suffering chronic hepatitis b represent patient pool significant risk morbidity mortality due underlying chronic viral infection chronic hepatitis b common china southeast asia commenced phase clinical trials china june licensed rights commercialize hepsera solely treatment hepatitis b china korea japan taiwan rest asia latin america certain territories glaxosmithkline gsk date gsk begun selling hepsera hong kong singapore philippines indonesia pakistan china hepsera granted class designation hepsera ultimately approved sale china would give gsk years market exclusivity hepsera respect competitors may otherwise able begin clinical development adefovir dipivoxil following approval receiving chinese governments approval phase study given approval move forward phase program completed patient enrollment march several existing therapies treating patients infected hbv compete hepsera treatments represent significant competition hepsera see competition exclusive worldwide license patent rights related technology adefovir dipivoxil iocbrega pay percentage net revenues sales hepsera iocbrega countries product patent protection including us european union addition pay small variable percentage net revenues us sales hepsera md anderson cancer center see academic consulting relationshipsmd anderson cancer center tamiflu oseltamivir phosphate tamiflu oral pill treatment prevention influenza b tamiflu class prescription drugs called neuraminidase inhibitors act disabling common strains flu virus preventing virus spreading patient used approved treatment influenza tamiflu shown reduce duration flu adults average reduce severity flu symptoms incidence secondary infectionswhen taken approved prevention influenza studies shown tamiflu effective preventing development flu tamiflu approved countries including us japan european union treatment influenza children adults tamiflu also approved us european union prevention influenza adolescents adults developed tamiflu roche roche exclusive right manufacture sell tamiflu subject obligation pay us percentage net revenues roche generates tamiflu sales date roches sales tamiflu significantly expectations moreover roche experienced problems manufacturing distribution tamiflu reduced net sales royalty material effect revenues see collaborative relationshipsroche several products available treat flu time shown effective safe neuraminidase inhibitors see competition tamiflu marketed alternative influenza vaccinations believe influenza vaccinations remain effective method preventing flu vistide cidofovir injection vistide antiviral medication treatment cmv retinitis patients aids cmv retinitis condition characterized lesions form patients retina affects persons weakened immune systems common patients aids left untreated cmv retinitis lead blindness vistide approved sale us european union several countries demand vistide low product revenues immaterial us commercial team sells vistide us outside us pfizer exclusive right sell vistide pfizer pays us percentage revenues generates sales vistide see collaborative relationshipspfizer active agent vistide cidofovir considered part us government strategy dealing potential bioterrorism attacks involving smallpox lifethreatening highly communicable infectious disease laboratory tests cidofovir demonstrated activity strains virus causes smallpox current clinical trials diluted smallpox vaccine conducted national institute allergy infectious diseases cidofovir considered potential treatment vaccinia infection adverse reaction sometimes caused smallpox vaccine additionally us national institutes health holds investigational new drug application ind allows emergency use cidofovir smallpox outbreaks without marketing approval fda know efficacy cidofovir might emergency use side effects may appear use cidofovir smallpox also predict whether us countries governments may stockpile vistide treatment smallpox daunoxome daunorubicin citrate liposome injection daunoxome liposomal formulation anticancer agent daunorubicin firstline therapy treating patients suffer certain types hiv associated kaposis sarcoma disease characterized widely disseminated lesions skin mucous membranes lymph nodes viscera life threatening patients suffering aids daunoxome approved sale us countries sold daunoxome us sell abroad independent distributors demand daunoxome low product revenues immaterial december made decision discontinue selling product products clinical trials fixeddose combination viread emtriva currently developing fixeddose combination viread emtriva completed bioequivalence study evaluated systemic exposure patients combination tablet comparison two individual products taken together currently conducting two week trials emtriva viread taken together separate pills emtricitabine hepatitis b emtricitabine shown inhibitor hepatitis b virus replication patients chronically infected hbv currently phase clinical development emtricitabine treatment chronic hepatitis b development activities undertaken emtricitabine treatment hiv also used assessment emtricitabine treatment chronic hepatitis b november announced results week clinical trial comparing efficacy safety emtricitabine mg day versus placebo patients chronic hepatitis b study ftcb believe second phase clinical trial necessary emtricitabine could submitted review regulatory agency second phase trial yet designed strategy emtricitabine treatment hepatitis b still evolving gs gs novel nucleotide analogue reverse transcriptase inhibitor processed body yields tenofovir active chemical yielded viread selectively within lymphatic cells chemical composition gs may allow cross cell membranes easily viread leading greater potency viread based data phase clinical trials gs begun developing phase program treatment hiv infection evaluate patients treatment naive highly resistant thymidine analogues research development seeking add existing portfolio products internal discovery clinical development programs active product acquisition inlicensing strategy acquisition triangle completed january research scientists foster city san dimas california durham north carolina engaged discovery development new molecules technologies hope lead new medicines novel formulations existing drugs therapeutic focus areas life threatening infectious diseases total research development rd expenses million compared million million nucleotide analogues scientists working proprietary nucleotide analogues develop treatments viral infections compounds treat viral infections interfering activity certain enzymes necessary virus grow believe small molecule nucleotide analogues offer advantages therapeutics first molecules demonstrated ability work bothinfected uninfected cells could enable us develop drugs treat patient infected virus also prevent healthy person becoming infected first place second drugs developed using molecules shown treatment activity patient longer periods time available drugs could enable us develop drugs require less frequent dosing thus convenient patients hiv protease inhibitors evaluating number small molecule compounds known protease inhibitors potential treatment hiv infection protease inhibitors act interfering activity protease enzyme like reverse transcriptase necessary replication hiv conducted number preclinical experiments compounds demonstrated potent antiviral activity lead candidate gs formerly known gs currently undergoing extensive preclinical evaluations submitted investigational new drug application fda gs january antiviral research undertaking additional research area treatment viral diseases many efforts focus potential targets hiv therapeutic drugs also significant research efforts aimed hepatitis c viral infection see collaborative relationshipschiron corporation commercial operations us international commercial sales operations marketing subsidiaries united kingdom germany italy spain france portugal greece australia commercial teams promote sell viread emtriva hepsera ambisome us europe australia ambisome also sold fujisawa us sumitomo japan gsk promote sell hepsera asia south america sell vistide us commercial partner pfizer sells vistide outside us commercial partner roche promotes sells tamiflu everywhere sold japan tobacco inc japan tobacco promote sell viread emtriva japan approved japanese regulatory authorities commercial teams promote viread emtriva hepsera direct field contact physicians hospitals clinics healthcare providers involved treatment patients hiv viread chronic hepatitis b hepsera also promote ambisome infectious disease specialists hematologists intensive care units hospitals home health care providers cancer specialists european commercial team supported medical sales operations marketing financial regulatory legal affairs manufacturing human resources information technology personnel located primarily european headquarters paris france us australian commercial teams supported worldwide headquarters foster city california countries outside us agreements thirdparty distributors including distributors certain countries marketing operations promote sell distribute viread emtriva hepsera ambisome international distribution agreements generally provide distributor exclusive right sell viread emtriva ambisome particular country several countries specified period time january announced program pursuant selling viread cost countries africa countries designated least developed countries united nations taking steps ensure viread product sold program used serve patients developing world diverted markets see international distribution support expand commercialization viread hepsera emtriva significantly increased sales force us devoting additional marketing resources us improve coverage healthcare professionals treating hivinfected hbvinfected patients also significantly increased size commercial operations europe manage commercialization viread emtriva hepsera european union april entered licensing agreement gsk gsk received exclusive rights commercialize hepsera asia latin america africa certain territories agreement retained rights hepsera us canada eastern western europe australia new zealand turkey gsk also received exclusive rights develop hepsera solely treatment chronic hepatitis b countries significant include china korea japan taiwan gsk full responsibility development commercialization hepsera territories july entered licensing agreement japan tobacco japan tobacco commercialize products gileads hiv portfolio japan agreement includes viread emtriva future coformulation two products japan tobacco submitted application viread expects submit application emtriva coformulation two products japanese regulatory authorities year us viread hepsera emtriva vistide daunoxome returnable original unopened containers expiration one year beyond expiration date damaged received customer customers may return ambisome shelf life expired product damaged defective customer receives ambisome approved shelf life months us months european countries daunoxome shelf life weeks us european countries viread shelf life months us european union hepsera shelf life months us european union emtriva shelf life months us european union date returns rebates discounts material financial results fujisawa establishes return policy ambisome north america roche establishes return policy tamiflu end flu season significant returns tamiflu roche reduce net sales royalty roche based additionally certain governmental agency customers state aids drug assistance programs entitled receive discounts required provide rebates state medicaid programs believe provide adequate provisions discounts rebates accordance revenue recognition policy collaborative relationships part business strategy establish collaborations companies assist clinical development andor commercialization certain products product candidates provide support research programs also evaluate opportunities acquiring companies products rights products technologies complementary business accounting relationships found note consolidated financial statements included report existing collaborative relationships follows archemix corporation october entered agreement archemix corporation archemix agreement granted archemix exclusive sublicense selex technology identify aptamers subject exclusion development areas rights already granted forfeited rights tothe selex technology derive license us university license equity holdings inc ulehi successor university technology corporation predecessor university research corporation financial terms agreement archemix provide lump sum payments us totaling million archemix made payments also received warrants purchase archemix stock agreement required agreements ulehi shared portion cash payments transferred warrants ulehi see academic consulting relationshipsuniversity license equity holdings inc chiron corporation august entered nonexclusive licensing agreement chiron corporation chiron research development commercialization small molecule therapeutics selected hepatitis c virus hcv drug targets agreement received nonexclusive rights chirons hcv technology drug screening purposes expect technology assist us research discovery effort identify develop potential hcv therapies terms agreement paid chiron upfront license fee agreed make milestone payments royalty payments product developed using licensed technology eyetech pharmaceuticals march entered agreement eyetech pharmaceuticals inc eyetech relating product named macugen developed treatment agerelated macular degeneration amd diabetic macular edema dme invented compound upon macugen based nx using selex technology licensed us ulehi see academic consulting relationshipsuniversity license equity holdings inc licensed nx eyetech developed macugen license us eyetech required pay us fees milestone payments well percentage revenue generate worldwide sales macugen addition eyetech granted us warrants purchase eyetech preferred stock agreement eyetech expires upon later ten years first commercial sale product developed date last patent expires agreement eyetech granted pfizer sublicense relating macugen december december connection sublicense entered license pfizer terms contained agreement eyetech december also entered agreement eyetech supply macugen eyetech three years fujisawa entered agreement granting fujisawa exclusive right promote sell ambisome canada primary responsibility promote sell ambisome us gilead copromoter fujisawa pays us approximately fujisawas net revenues sales ambisome us reserved right promote sell ambisome rest world pay fujisawa net revenues ambisome sales significant asian markets including japan korea taiwan china india manufacture ambisome sold worldwide sell ambisome fujisawa sale us price equal cost manufacture product sale canada price equal cost manufacture product plus specified percentage agreement fujisawa terminates last patent covering ambisome us japan expires glaxosmithkline april entered licensing agreement gsk giving exclusive rights commercialize hepsera solely treatment chronic hepatitis b asia latin america certain territories addition fees milestone payments contract revenues gsk required pay us percentage revenue generate sales hepsera licensed territories agreement gsk entered clinical commercial supply agreement gsk required supply clinical commercial requirements fully burdened cost subject reasonable forecasting ordering procedures agreement gsk expires individual country basis later patent expiration ten years first commercial sale particular country addition gsk right electively terminate agreement months notice gilead subject fee elective termination circumstances early term agreement japan tobacco july entered licensing agreement japan tobacco japan tobacco obtained rights commercialize products gileads hiv portfolio japan agreement includes viread emtriva future coformulation two products received upfront fee entitled receive milestone payments japan tobacco also required make payments us based product sales japan japan tobacco submitted application viread expects submit application emtriva coformulation two products japanese regulatory authorities year contemplated license agreement december completed supply agreement japan tobacco supply japan tobacco viread emtriva future coformulation two products osi pharmaceuticals december sold osi pharmaceuticals osi pipeline clinical stage oncology products related intellectual property well boulder colorado operations consideration assets received osi million cash shares osi common stock additionally osi required pay us additional million either cash combination cash osi common stock upon achievement osi certain milestones related development nx advanced oncology product candidates separately manufacturing agreement osi agreed produce osi liposomal formulations two products including nx manufacturing facility san dimas california pfizer entered agreement pfizer formerly pharmacia corporation relating vistide agreement pfizer exclusive right market sell vistide countries outside us subject payment us percentage net revenues required sell pfizer bulk vistide maintain vistide patents agreement pfizer expires individual country basis upon patent expiration ten years first commercial sale countries product covered patent addition pfizer may terminate agreement whole upon six months notice upon notice individual country basis three months applying marketing approval competitive product roche entered collaboration agreement roche granting roche exclusive worldwide rights tamiflu well proprietary influenza neuraminidase inhibitors december received license fees milestone payments roche totaling million relating executionof agreement regulatory filings approvals tamiflu roche also funded research development costs tamiflu including reimbursement us million period january december agreement roche responsible pricing manufacturing promoting selling tamiflu worldwide basis pays us percentage net revenues sales tamiflu subject reduction certain defined manufacturing costs agreement roche terminates individual country basis later patent expiration ten years first commercial sale particular country addition roche right terminate agreement entirety individual country basis prior expiration time upon months notice sumitomo entered agreement sumitomo gave sumitomo exclusive right develop market ambisome japan addition milestone payments sumitomo required pay us percentage revenue generate japanese sales ambisome ambisome approved sale japan would manufacture ambisome sale sumitomo japan price would charge sumitomo supply ambisome percentage revenues would required pay us would determined price ambisome japan agreement sumitomo terminates later patent expiration japan ten years first commercial sale japan academic consulting relationships supplement research development efforts part regular business enter arrangements universities medical research institutions arrangements often provide us rights patents patent applications technology owned institutions return payments fees relating use rights emory university university georgia research foundation inc emtricitabine april triangle obtained acquired part acquisition triangle exclusive worldwide license emory universitys rights purified forms emtricitabine use hiv hepatitis b fields obligated make certain milestone royalty payments emory including annual minimum royalties beginning third year first fda registration granted antihiv product incorporating emtricitabine technology us third year first registration granted antihepatitis b product incorporating emtricitabine technology certain major market countries hiv hepatitis b indications respectively triangle began paying license maintenance fees development milestones yet achieved may emory gsk settled litigation pending united states district court relating emtricitabine became exclusive licensee us foreign patents patent applications filed burroughs wellcome co use emtricitabine treat hepatitis b license settlement agreements emory also given access development clinical data drug substance held gsk relating emtricitabine may emory gsk shire pharmaceuticals group plc shire settled worldwide patent disputes involving lamivudine emtricitabine terms settlement emory received exclusive license shire shires patents relating emtricitabine methods use manufacture shire gsk received exclusive licenses emorys patents relating lamivudine terms license agreement emory automatically acquired exclusive sublicense shire patents relating emtricitabine granted terms settlement thereby resolving previously pending patent disputes regarding emtricitabine license agreement emory terminates upon later patent expiration expiration obligation pay royalties addition right terminate agreement entirety respect one indications hiv hbv one countries prior expiration time upon days notice amdoxovir march triangle entered acquired part acquisition triangle license agreement emory university georgia research foundation inc ugrf pursuant received exclusive worldwide license emorys ugrfs rights series nucleoside analogues including amdoxovir dxg ie active antihiv agent use hiv hepatitis b fields march triangle began paying license maintenance fees development milestones yet achieved january announced intent terminate license agreement amdoxovir md anderson cancer center entered agreement md anderson cancer center relating hepsera agreement currently pay md anderson cancer center percentage net revenues based upon sales hepsera agreement md anderson cancer center terminates later patent expiration ten years first commercial sale iocbrega entered agreements iocbrega relating viread hepsera vistide agreements received iocbrega exclusive right manufacture use sell nucleotide compounds covered agreements currently pay percentage net revenues based upon sales viread hepsera vistide iocbrega agreements iocbrega terminate individual country basis later patent expiration ten years first commercial sale addition iocbrega may terminate licenses particular product key market absence commercial sales product within months regulatory approval university license equity holdings inc ongoing collaborative arrangement university license equity holdings inc ulehi successor university technology corporation predecessor university research corporation technology holding company university colorado boulder relating selex technology identify aptamers arrangement ulehi granted us present future rights inventions covered patents patent applications selex technology improvements selex technology makes discovers oligonucleotides molecules makes using selex technology computer software related selex technology required pay ulehi certain variable royalties based revenues generated sales products derived using selex technologydeveloping world collaborations bill melinda gates foundation family health international october entered agreement bill melinda gates foundation family health international fhi provide viread fhis multinational clinical trial evaluating vireads effectiveness method reducing risk hiv infection among sexually active adults regularly exposed hiv clinical trials conducted fhi funded million threeyear grant gates foundation dart study november entered collaborative agreement medical research council mrc united kingdom boehringer ingelheim gmbh gsk connection fiveyear clinical study conducted mrc antiretroviral hiv therapy africa trial called dart trial development antiretroviral therapy africa aimed studying clinical versus laboratory monitoring practices structured treatment interruptions versus continuous antiretroviral therapy adults hiv infection subsaharan africa provide viread cost dart study institute one world health january entered agreement institute one world health pursuant provide ambisome cost phase clinical trial evaluating ambisome treatment visceral leishmaniasis paromomycin india greatest global burden visceral leishmaniasis clinical trial conducted institute one world health partnership world health organization international distribution various agreements distributors europe asia latin america middle east africa grant distributors exclusive right sell viread emtriva hepsera ambisome particular country countries specified period time agreements also provide collaborative efforts us distributor obtaining regulatory approval product particular country marketing product country agreements establish price distributor must pay product require us deliver quantities product ordered distributor manufacturing ambisome manufacture ambisome commercial quantities two separate adjacent facilities san dimas california medicines control agency united kingdom fda approved commercial production ambisome facility produced import ambisome european union manufacturing facility dublin ireland perform quality control testing final labeling packaging distribution european union elsewhere discontinued manufacturing daunoxome use commercially available materials equipment manufacture products currently obtain amphotericin b cholesterol use manufacture ambisome single approved suppliers ambisome sold freezedried product currently freezedry ambisome san dimas manufacturing facility also use third party freezedry additional product needed given current projections ambisome demand believe sufficient capacity meet future demand also option installing additional freezedrying capacity san dimas additional supply become necessary unable install additional freeze drying capacity san dimas locate appropriate third parties meet need ability meet increased ambisome demand would diminished antiviral products contract third parties manufacture antiviral drugs clinical commercial purposes including viread emtriva hepsera vistide manufacture viread tablets single contract manufacturer us european union sales distribution territories addition second contract manufacturer europe european union distributed product approved respective agencies obtained qualification us european union two contract manufacturers adefovir dipivoxil active ingredient hepsera one contract manufacturer final hepsera drug product commercial supply seeking qualify second supplier entered agreement abbott laboratories abbott manufacture emtricitabine bulk drug substance final drug product us qualified second contract manufacturer bulk drug substance us european union two suppliers approved fda european union manufacture cidofovir bulk drug substance used vistide single fda emea approved supplier vistide drug product january roche announced due production problems liquid suspension form tamiflu approved treatment children young one yearold available however liquid suspension form tamiflu returned market time flu season production issues affect availability tablet form tamiflu adults adolescents years older japan flu season particularly severe roches sublicensee chugai corporation unable meet heightened demand satisfactorily january chugai issued press release attributing failure part manufacturing problems november chugai announced recall tamiflu problems japan reduced net sales royalty roche royalties roche tamiflu expectations date production commercialization issues material effect earnings expect material effect earnings future commercialscale manufacturing facilities antiviral products future antiviral products need develop additional manufacturing capabilities establish additional third party suppliers order manufacture sufficient quantities product candidates undertake clinical trials manufacture sufficient quantities products approved commercial sale unable develop manufacturing capabilities internally contract large scale manufacturing third parties acceptable terms future antiviral products ability conduct largescale clinical trials meet customer demand commercial products would adversely affected believe technology use manufacture products compounds proprietary antiviral products disclosed necessary aspects technology contract manufacturers enable manufacture products compounds us agreements manufacturers intended restrict using revealing technology certain manufacturers comply restrictions addition manufacturers could develop technology related work perform us may need manufacture ourproducts compounds could required enter agreement manufacturer wanted use technology allow another manufacturer use technology manufacturer could refuse allow us use technology could demand terms use technology acceptable believe compliance material environmental regulations related manufacture products patents proprietary rights patents proprietary rights important business properly designed enforceable patent difficult competitors use technology create competitive products difficult competitors obtain patent prevents us using technology create part business strategy actively seek patent protection us internationally file additional patent applications appropriate cover improvements compounds products technology also rely trade secrets internal knowhow technological innovations agreements third parties develop maintain protect competitive position ability competitive depend success strategy number patents patent applications rights patents related compounds products technology certain issued patents enforceable provide adequate protection pending patent applications result issued patents following table shows actual estimated expiration dates us europe primary patents patents may issue pending applications cover compounds marketed products product candidates us patent expiration european patent expiration products viread hepsera ambisome tamiflu vistide emtriva patents covering viread hepsera vistide emtriva held third parties acquired exclusive rights patents agreements parties see collaborative relationships academic consulting relationships patents cover active ingredients ambisome instead hold patents liposomal formulations compound also protect formulations trade secrets patent filings covering forms hepsera china certain asian countries although applications pending various asian countries including china relate specific forms formulations hepsera asia major market hbv therapies may obtain patents compounds many years obtain marketing approval limits time prevent companies developing compounds therefore reduces value product however apply patent term extensions example extensions patents vistide granted us number european countries compensating part delays obtaining marketing approval similar patent term extensions may available products developing certain obtain also important infringe patents proprietary rights others violate agreements grant proprietary rights us infringe patents violate agreements could prevented developing selling products using processes covered patents agreements could required obtain license third party allowing us use technology certain required could obtain license thirdparty technology could obtain one reasonable cost able obtain required license could adversely affected patent applications confidential least period time including sometimes us patent issues may pending patent applications patents eventually issue prevent us developing selling certain products unless obtain license use patented technology patents relating pharmaceutical biopharmaceutical biotechnology products compounds processes cover existing compounds products processes likely file future always provide complete adequate protection future litigation reexamination proceedings regarding enforcement validity existing patents future patents could invalidate patents substantially reduce protection addition pending patent applications patent applications filed collaborative partners may result issuance patents may result patents provide adequate protection result may able prevent third parties developing compounds products developing also rely unpatented trade secrets improvements unpatented internal knowhow technological innovation particular great deal liposomal manufacturing expertise key component liposomal technology covered patents instead protected trade secret protect rights mainly confidentiality agreements corporate partners employees consultants vendors agreements provide confidential information developed made known individual course relationship us kept confidential used disclosed third parties except specified circumstances case employees agreements provide inventions made individual employed us exclusive property certain parties comply confidentiality agreements would adequate remedies breach trade secrets otherwise become known independently discovered competitors research development agreements inventions discovered certain cases become jointly owned us corporate partner cases become exclusive property one us difficult determine owns particular invention disputes could arise regarding inventions competition products development programs target number diseases conditions including viral fungal infections many commercially available products diseases large number companies institutions spending considerable amounts money resources develop additional products treat diseases current products compete available products based primarily efficacy safety tolerability acceptance doctors patient compliance patent protection ease use price insurance reimbursement coverage distribution marketing adaptability various modes dosing products market future also compete products offered competitors competitors introduce data shows improved characteristics products improve increase marketing efforts simply lower price products sales products could decrease also certain products may develop future compare favorably products offered competitors existing future products compare favorably new products developed competitors ability competitive also depends upon ability attract retain qualified personnel obtain patent protection otherwise develop proprietary products processes secure sufficient capital resources substantial period takes develop product viread emtriva hiv competitive landscape becoming crowded complicated treatment trends continue evolve growing number antihiv drugs currently sold advance stages clinical development branded drugs available us zerit stavudine dt sold bristolmyers squibb bms fixed combination products combivir azt tc trizivir azt tc abc sold gsk represent direct competition viread companies process launching formulations existing drugs indicated fda oncedaily oral dosing include gsks mg dose epivir tc bmss new extended release formulation zerit recently approved antiretroviral products include atazanivir qd protease inhibitor bms fuzeon injectable integrase inhibitor rochetrimeris gsk filed application approval oncedaily dose ziagen abacavir well new fixed dose combination ziagen epivir companies competing hiv therapeutic category pfizer merck boehringeringelheim abbott ambisome ambisome faces strong competition several current expected competitors current competitors include conventional amphotericin b made bms numerous generic manufacturers caspofungin product developed merck marketed cancidas us caspofungin elsewhere voriconazole developed pfizer marketed vfend lipidbased amphotericin b products approved us throughout europe including abelcet sold enzon corp us canada japan medeus pharma ltd europe amphotec sold intermune pharmaceuticals inc presently unapproved expected competitors include class treatments called echinocandins including fujisawas micafungin received marketing approval japan october review regulatory approval us canada anidulafungin vircuron inc formerly versicor inc product candidate evaluated multiple latestage clinical trials finally schering plough developing noxafil posaconazole currently phase trialscompetition current expected competitors eroded likely continue erode revenues receive sales ambisome hepsera hepsera faces significant competition existing therapies treating patients infected hbv significantly epivirhbv lamivudine developed gsk collaboration shire pharmaceuticals sold major countries throughout north south america europe asia orally administered nucleoside analogue inhibits hbv dna polymerase introna interferon alfab sold schering plough major countries throughout north south america europe asia introna injectable drug immunomodulatory effects hepsera may also face competition clinicalstage candidates including bristolmyers squibbs entecavir idenixs ldt two oral nucleoside analogues currently phase trials competition include roches pegasys pegylated interferon alfaa currently studied chronic hepatitis b tamiflu tamiflu competes relenza antiflu drug sold gsk relenza neuraminidase inhibitor delivered orallyinhaled dry powder vistide vistidecompetes number drugs also treat cmv retinitis including ganciclovir sold intravenous oral formulations roche ocular implant bausch lomb incorporated valganciclovir also marketed roche foscarnet intravenous drug sold astrazeneca formivirsen drug injected directly eye sold cibavision number companies pursuing development technologies competitive research programs competing companies include specialized pharmaceutical firms large pharmaceutical companies acting either independently together biopharmaceutical companies furthermore academic institutions government agencies public private organizations conducting research may seek patent protection may establish collaborative arrangements competitive products programs anticipate face increased competition future competitors introduce new products market new technologies become available determine existing products new products competitors develop effective effectively marketed sold develop competitive products could render technology products obsolete noncompetitive recover money resources used develop products government regulation operations activities subject extensive regulation numerous government authorities us countries us drugs subject rigorous fda regulation federal food drug cosmetic act federal state statutes regulations govern testing manufacture safety effectiveness labeling storage record keeping approval advertising promotion products result regulations product developmentand product approval process expensive time consuming fda must approve drug sold us general process approval follows preclinical testing test drug candidate humans must study drug laboratory experiments animals generate data support drugs potential safety benefits submit data fda investigational new drug application ind seeking approval test compound humans clinical trials fda accepts investigational new drug application study drug human clinical trials determine drug safe effective clinical trials involve three separate phases often overlap take many years expensive three phases subject considerable regulation follows phase drug given small number healthy human subjects patients test safety dose tolerance pharmacokinetics metabolism distribution excretion phase drug given limited patient population determine effect drug treating disease best dose drug possible side effects safety risks drug phase compound appears effective safe phase clinical trials phase clinical trials commenced confirm results phase clinical trials longterm involve significantly larger population conducted numerous sites different geographic regions carefully designed provide reliable conclusive data regarding safety benefits drug uncommon drug appears promising phase clinical trials fail rigorous reliable phase clinical trials fda approval process believe data phase clinical trials show adequate level safety effectiveness file new drug application nda fda seeking approval sell drug particular use fda review nda often hold public hearing independent advisory committee expert advisors asks additional questions regarding drug committee makes recommendation fda binding fda generally followed fda fda agrees compound required level safety effectiveness particular use allow us sell drug us use unusual however fda reject application believes drug safe enough effective enough believe data submitted reliable conclusive point process development drug could stopped number reasons including safety concerns lack treatment benefit certain clinical trials conducting conduct future completed successfully within specified time period may choose fda may require us delay suspend clinical trials time appears patients exposed unacceptable health risk drug candidate appear sufficient treatment benefit fda may also require us complete additional testing provide additional data information improve manufacturing processes procedures facilities require extensive postmarketing testing surveillance monitor safety benefits product candidates determine new drug application contain adequate evidence safety benefits drug addition even fda approves drug could limit uses drug approvals also withdrawn fda believe complying regulatory standards problems uncovered occur approval addition obtaining fda approval drug manufacturing facilities drug sell including companies manufacture drugs us well must approved fda subject periodic inspections fda foreign establishments manufacture products sold us must also approved fda subject periodic regulatory inspection manufacturing facilities located california including san dimas facility foster city facility also must licensed state california compliance local regulatory requirements drugs treat serious lifethreatening diseases conditions adequately addressed existing drugs may designated fast track products fda may eligible priority six month review accelerated approval case viread drugs receiving accelerated approval must monitored postmarketing clinical trials order confirm safety benefits drug also subject federal state local regulations regarding workplace safety protection environment use hazardous materials chemicals viruses various radioactive compounds research development activities eliminate risk accidental contamination injury materials misuse accidents involving materials could lead significant litigation fines penalties drugs also subject extensive regulation outside us european union centralized approval procedure authorizes marketing product countries european union includes major countries europe procedure used decentralized system approval one country european union used obtain approval another country european union simplified application process approval centralized procedure pricing reimbursement approvals also required countries vistide viread hepsera emtriva approved european union centralized procedure viread hiv drug reviewed accelerated approval european union hepsera received traditional review emtriva pricing reimbursement insurance companies health maintenance organizations hmos thirdparty payors governments seek limit amount charge drugs example certain foreign markets pricing negotiations often required obtain approval product us expect continue number federal state proposals implement drug price control addition managed care organizations becoming common us continue seek lower drug prices announcement proposals efforts cause stock price decrease proposals adopted revenues could decrease ability sell drugs also depends availability reimbursement governments private insurance companies governments insurance companies often demand rebates predetermined discounts list prices expect products developing particularly aids indications subject reimbursement issues certain products obtain regulatory approval reimbursed governmentand insurance companies regulatory approval prices generally required foreign countries particular certain countries condition approval product agreement seller sell product certain price country past required price reductions connection product approval certain regulatory authorities future establish lower prices regulatory action reducing price products one country practical effect requiring us reduce prices countries european governments notably germany italy implemented considering legislation would require pharmaceutical companies sell products subject reimbursement mandatory discount mandatory discounts would reduce revenue receive drug sales certain developing countries significantly affected hiv aids parallel importing generic competition may occur adversely affect revenues sales market share viread employees february approximately fulltime employees believe good relations employees website website address wwwgileadcom make available free charge website annual report quarterly reports form q current reports form k director officers section reports amendments reports soon reasonably practicable filing providing hyperlink edgar website directly reports risk factors affect gilead evaluating business carefully consider following risks addition information report following risks could materially adversely affect business operating results financial condition substantially revenues derived sales two products unable maintain continue growing sales viread maintain sales ambisome results operations may adversely affected currently dependent sales two lead products viread ambisome support existing operations together products accounted approximately total revenues year ended december unable continue growing viread revenues maintain ambisome sales results operations likely suffer may need scale back operations viread product sales year ended december million total revenues ambisome product sales royalties year ended december million total revenues may able maintain growth rate viread current sales level ambisome reasons stated risk factor section particular following reasons face significant competition businesses substantially greater resources example experienced declining sales volumes ambisome due part introduction new european competitors volume basis ambisome sales decreased europe compared viread ambisome used longer period time additional studies conducted new issues respect safety resistance interactions drugs may arise could cause us provide additional warnings labels narrow approved indications halt sales product could reduce revenues product matures private insurers government reimbursers may reduce amount reimburse patients products increase pressure us reduce prices example authorities germany italy reduced amount reimbursement provide patients using viread expect similar reductions france fail commercialize new products expand indications existing products prospects future revenues stock price may adversely affected introduce new products increase revenues existing products may able grow revenues order expand products begun marketing hepsera treatment chronic hepatitis b emtriva treatment hiv united states european union addition developing coformulation tenofovir emtricitabine failure achieve objectives expected may material adverse effect business results operations may able achieve objectives following reasons hepsera new drug faces competitive marketplace less experience established competitors example hepsera primarily competes lamivudine united states interferonalfa b european hepatitis b market hepseras primary advantage lamivudine patients far less likely develop resistance hepsera lamivudine however lamivudine market longer hepsera lamivudines resistance problems surface product marketed hepsera may continue show superior resistance properties lamivudine hepseras primary advantages interferonalfa b greater safety tolerability oral dosing newer versions interferon pegylatedinterferon development may prove safer tolerable offer onceweekly injectable dosing marketing treatment hepatitis b also difficult since many infected individuals diagnosed consensus among physicians appropriate methods treatment physical combination emtricitabine tenofovir may technically feasible costeffective addition may able develop chemistry manufacturing bioequivalence package shows coformulated tablet gives exposure tenofovir emtricitabine two drugs given individually support regulatory approval completed stability studies necessary support approval coformulation tenofovir emtricitabineif fail increase sales hepsera obtain regulatory approval successfully market coformulation emtricitabine tenofovir may able increase revenues expand research development efforts significant safety issues arise marketed products sales may decline would adversely affect results operations data support marketing approvals products including viread ambisome hepsera emtriva form basis safety warnings product labels obtained controlled clinical trials limited duration case viread limited postapproval use following approval products used longer periods time many patients taking numerous medicines underlying health problems monitored dosing compliance new safety issues reported postmarketing use rule contributory role products may required provide additional warnings labels narrow approved indications could reduce market acceptance products example observe kidney toxicity clinical trials viread kidney toxicity reported postapproval use viread viread label updated include warning serious safety issues marketed products arise sales products could halted us regulatory authorities discontinued development adefovir dipivoxil mg treatment hiv infection due concerns kidney toxicity arising studies mg dose adefovir dipivoxil used hepsera associated significant kidney toxicity clinical trials date patients preexisting kidney problems taking drugs known cause kidney toxicity however kidney toxicity may develop broader hepatitis b patient population operations depend compliance complex fda comparable international regulations failure obtain broad approvals timely basis achieve continued compliance could delay commercialization products products develop must approved marketing sale regulatory authorities subject extensive regulation fda comparable regulatory agencies countries continuing clinical trials ambisome viread hepsera emtriva currently approved additional uses anticipate file marketing approval additional countries additional products next several years products may fail receive marketing approval timely basis also current filing strategy coformulation tenofovir emtricitabine based data completed studies fda requires additional pivotal studies combination product regulatory filing delayed regulatory authorities outside us european union may approve emtricitabine treatment hiv sufficient efficacy advantages currently marketed lamivudine product also may able obtain regulatory approvals necessary expand commercial efforts new markets failures delays limitations well regulatory changes actions recalls could delay commercialization products adversely affect results operations addition marketed products sell products subject extensive regulation review later discovery previously unknown problems products problems promotional activities may result restrictions products including withdrawal products market example august fda issued written warning concerning promotional activities viread fail comply applicable regulatory requirements could subject penalties including fines suspensions regulatory approvals product recalls seizure products criminal prosecution addition named multiparty lawsuit alleging inflated reimbursement rates medicaid program certain pharmaceuticals manufacture results clinical trials uncertain may support continued development product pipeline would adversely affect prospects future revenue growth required demonstrate safety effectiveness products develop intended use extensive preclinical studies clinical trials results preclinical early clinical studies always accurately predict results later largescale clinical trials even successfully completed largescale clinical trials may result marketable products number companies industry suffered setbacks advanced clinical trials despite promising results earlier trials example fda denied approval adefovir dipivoxil mg drug developed gilead treatment hiv based concerns regarding kidney toxicity may future seek clinical development similar compounds also potential kidney toxicity adverse effects products development fail achieve primary endpoint clinical trials safety issues arise commercialization drug candidate could delayed halted manufacturing problems could delay product shipments regulatory approvals may adversely affect results operations depend third parties perform manufacturing activities effectively timely basis third parties fail perform required could impair ability deliver products timely basis cause delays clinical trials applications regulatory approval events could harm competitive position manufacturing process pharmaceutical products highly regulated regulators may shut manufacturing facilities believe comply regulations fdas current good manufacturing practices extensive regulations governing manufacturing processes stability testing recordkeeping quality standards addition manufacturing operations subject routine inspections regulatory agencies similar regulations effect countries viread hepsera vistide emtriva rely third parties manufacture bulk drug substance final drug product clinical commercial purposes addition roche responsible manufacturing tamiflu thirdparty manufacturers may develop problems control problems may adversely affect business example january roche announced due production problems liquid suspension form tamiflu approved treatment children young one year old available japan flu season particularly severe roches sublicensee chugai corporation unable meet heightened demand satisfactorily january chugai issued press release attributing failure part manufacturing problems problems japan reduced net sales royalty roche manufacture ambisome facilities san dimas california formulation manufacturing facilities us manufacturing facility ireland performs certain quality control testing labeling packaging addition use third parties alternate contract suppliers fill freeze dry certain batches product event natural disaster including earthquake equipment failure strike difficulty may unable replace manufacturing capacity timely manner would unable manufacture ambisome meet market needs may able obtain materials necessary manufacture products could limit ability generate revenues many materials utilize operations made one facility example depend single suppliers high quality amphotericin bdistearoylphosphatidylcholine high quality cholesterol used manufacture one liposomal products suppliers key components materials must named new drug application filed fda product significant delays occur qualification new supplier required supplies suppliers interrupted reason may unable ship viread ambisome hepsera emtriva vistide supply products development clinical trials may need develop additional manufacturing capacity existing future products increase expenses evaluated past continue evaluate feasibility acquiring manufacturing capabilities support production products principally viread emtriva facilities may required increase production capacities order support clinical trials produce products commercial sale acceptable cost manufactured products past developing technological capabilities building purchasing facility increase expenses guarantee able recover investment manufacturing capabilities depend relationships companies sales marketing performance revenues failure maintain relationships would negatively impact business rely number significant collaborative relationships major pharmaceutical companies sales marketing performance include collaborations fujisawa sumitomo ambisome gsk hepsera roche tamiflu pfizer vistide japan tobacco viread emtriva certain countries rely international distributors sales ambisome viread emtriva european countries intend rely international distributors sales hepsera relationships also involve clinical development products partners reliance collaborative relationships poses number risks including able control whether corporate partners devote sufficient resources programs products disputes may arise future respect ownership rights technology developed corporate partners disagreements corporate partners could lead delays termination research development commercialization product candidates result litigation arbitration contracts corporate partners may fail provide significant protection may fail effectively enforced one partners fails perform corporate partners considerable discretion electing whether pursue development additional products may pursue alternative technologies products either collaboration competitors corporate partners marketing rights may choose devote fewer resources marketing products products development distributors corporate partners may unable pay us given risks great deal uncertainty regarding success current future collaborative efforts efforts fail product development commercialization new products could delayed revenue existing products including viread emtriva hepsera ambisome tamiflu could decline april licensing agreement gsk gave gsk right control clinical regulatory development commercialization hepsera territories asia africa latin america include major markets hepsera china japan taiwan korea success hepsera territories depend almost entirely efforts gsk regard gsk promotes epivirhbv product competes hepsera consequently gsks marketing strategy hepsera may influenced promotion epivirhbv receive royalties gsk equal percentage net sales made gsk gsk fails devote sufficient resources succeed developing commercializing hepsera territories potential revenues sales hepsera may substantially reduced expenses associated clinical trials sales fluctuations result inventory levels held wholesalers may cause earnings fluctuate could adversely affect stock price clinical trials required regulatory approval products extremely expensive difficult accurately predict control amount timing expenses quarter quarter uneven unexpected spending programs may cause operating results fluctuate quarter quarter addition substantial portion sales activity united states conducted three distributors amerisource bergen corp mckesson corp cardinal health inc inventory levels held wholesalers may fluctuate significantly could cause sales result operating results fluctuate unexpectedly quarter quarter example based review ndc prescription trends ims inventory data actual viread sales believe quarter ended june wholesalers built inventory levels estimated months believe inventory buildup followed equivalent possibly greater inventory reduction quarter ended september approximately half product sales occur outside us currency fluctuations may cause earnings fluctuate could adversely affect stock price significant percentage product sales denominated foreign currencies increases value us dollar foreign currencies past reduced future may reduce us dollar equivalent sales negatively impact financial condition results operations use foreign currency forward contracts hedge percentage forecasted international sales primarily denominated euro currency also hedge portion accounts receivable balances denominated foreign currencies reduces eliminate exposure currency fluctuations date sale recorded date cash collected additionally mitigate impact currency rate fluctuations cash outflows certain foreign currencydenominated raw materials purchases enter foreign exchange forward contracts hedge foreign currencydenominated accounts payable although use forward contracts reduce impact foreign currency fluctuations future results efforts may successful fluctuations could adversely affect results operations face credit risks european customers may adversely affect results operations particularly subject credit risk european customers european product sales government owned supported customers greece spain portugal italy subject significant payment delays due government funding reimbursement practices accounts receivable fromgovernment owned supported customers countries totaled million december significant changes occur reimbursement practices european governments government funding becomes unavailable may able collect amounts due us customers results operations would adversely affected plan supply viread cost certain developing countries may expose us liability would material adverse affect results operations financial condition launching distribution program pursuant supply viread cost countries africa countries designated least developed countries united nations supply distribution drugs resourcepoor environment complicated undertaking program develops could face unforeseen challenges risks could give rise unforeseen liabilities example patients less developed countries using viread may closely supervised doctor would developed nations accordingly may increased likelihood viread related complications going undetected untreated could result significant liability gilead product revenues could reduced imports countries products available lower prices prices products based local market economics competition sometimes differ country country sales countries relatively higher prices may reduced products imported countries lower price markets cases pharmaceutical products sold steeply discounted prices developing world reexported european countries could resold much higher prices happens products particularly viread agreed provide cost countries africa countries designated least developed countries united nations revenues would adversely affected addition european union required permit cross border sales allows buyers countries governmentapproved prices products relatively high purchase products legally countries must sold lower prices additionally us consumers able purchase products including hiv medicines internet pharmacies countries substantial discounts crossborder sales could adversely affect revenues countries may required grant compulsory licenses hiv products face generic competition hiv products number developing countries government officials groups suggested pharmaceutical companies make drugs hiv infection available low cost cases governmental authorities indicated pharmaceutical companies make hiv drugs available low cost patents might enforceable prevent generic competition major pharmaceutical companies greatly reduced prices hiv drugs certain developing countries certain countries permit enforcement patents sales products countries could reduced generic competition alternatively governments countries could require grant compulsory licenses allow competitors manufacture sell versions products countries thereby reducing sales could respond governmental concerns reducing prices products addition reducing sales compulsory licenses may increase risk counterfeiting would longer control manufacturing distribution markets addition countries canada considering amending patent laws permit export otherwise patented products countries developing world situations results operations could adversely affected existing products subject reimbursement government agencies third parties pharmaceutical pricing reimbursement pressures may reduce profitability successful commercialization products depends part availability governmental third party payor reimbursement cost products related treatments government health administration authorities private health insurers organizations generally provide reimbursement government authorities thirdparty payors increasingly challenging price medical products services particularly innovative new products therapies resulted lower average sales prices example majority sales ambisome vistide significant percentage sales viread hepsera subject reimbursement government agencies resulting significant discounts list price rebate obligations business may adversely affected increase us international pricing pressures pressures arise rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid health care reform pharmaceutical reimbursement pricing general us recent years new legislation proposed federal state levels would effect major changes health care system either nationally state level proposals included prescription drug benefit proposals medicare beneficiaries recently passed congress additionally states enacted health care reform legislation federal state developments possible results operations could adversely affected future health care reforms europe success hepsera tamiflu emtriva viread also depend largely obtaining maintaining government reimbursement many european countries including united kingdom france patients reluctant pay prescription drugs pocket also expect success products development particularly europe depend ability obtain reimbursement even reimbursement available reimbursement policies may adversely affect ability sell products profitable basis addition many international markets governments control prices prescription pharmaceuticals markets regulatory marketing approval received pricing negotiations governmental authorities take twelve months longer foreign governments passed considering legislation require us sell products subject reimbursement mandatory discount sales competing products attempts gain market share introductory pricing programs competitors could also require us lower prices countries could adversely affect results operations may able obtain effective patents protect technologies use competitors patents companies could require us stop using pay use required technology success depend significant degree ability obtain patents licenses patent rights preserve trade secrets operate without infringing proprietary rights others rights us foreign issued patents filed continue file patent applications us abroad relating technologies risk however patents may issue applications patents sufficient protect technology patent applications confidential least period time sometimes us patent issues result may know competitors filed patent applications technology covered pending applications first invent technology subject patent applications competitors may filed patent applications received patents may obtain additional patents proprietary rights block compete patents patent filings china certain asian countries covering forms adefovir dipivoxil active ingredient hepsera although applications pending various asian countries relate various forms formulations adefovir dipivoxil asia major market therapies hepatitis b indication hepsera developed may obtain patents certain products many years marketing approval obtained products patents limited life may begin run prior commercial sale commercial value product may limited addition patents may provide adequate protection certain countries africa asia including china competitors may file patent applications covering technology may participate interference proceedings litigation determine right patent litigation interference proceedings expensive even ultimately successful success depends large part ability operate without infringing upon patents proprietary rights third parties infringe patents others may prevented commercializing products may required obtain licenses third parties may able obtain alternative technologies required license reasonable terms fail obtain licenses alternative technologies may unable develop commercialize products addition use significant proprietary technology rely unpatented trade secrets proprietary knowhow protect certain aspects production technologies trade secrets may become known independently discovered competitors may face significant liability resulting products may covered insurance successful claims could materially reduce earnings testing manufacturing marketing use viread ambisome hepsera emtriva tamiflu vistide well products development involve substantial risk product liability claims claims may made directly consumers healthcare providers pharmaceutical companies others although maintain product liability insurance successful product liability claim us may covered insurance could require us pay amounts beyond provided insurance either could impair financial condition ability clinically test market products item properties corporate headquarters including principal executive offices research facilities located foster city california location approximately square feet space proximately located buildings currently occupy buildings also tenant occupying remaining buildings also occupy facilities san dimas california location lease approximately square feet space houses research development activities manufacturing certain administrative functions leases expire may november renewal options present addition lease adjacent warehouse facility square feet space use product distribution administrative functions lease expires may two additional fiveyear extensions durham north carolina lease approximately square feet administrative office laboratory space sublease approximately square feet third parties lease expires october gilead option renew two sevenyear terms addition lease approximately square feet space sales marketing regulatory finance information technology human resource operations europe australia including prepaid year lease square foot manufacturing distribution facility ireland leases various expiration dates believe facilities adequate suitable least current nearterm future needs item legal proceedings september gilead entered settlement agreement release university license equity holdings inc ulehi archemix corporation concerning rights identify aptamers using selex technology licensed ulehi gilead settlement agreement release resolves disputes among parties arising gileads assignment rights identify certain aptamers archemix september county westchester new york westchester served gilead complaint filed united states district court southern district new york alleges gilead large number pharmaceutical manufacturer defendants report prices products overstate average wholesale price awp allegedly inflating reimbursement rates medicaid program causing westchester pay artificially inflated prices covered drugs including case gilead viread addition westchester argues defendants including gilead accurately report best price medicaid program complaint asserts varying claims federal rico statutes state law corollaries well state law claims deceptive trade practices common law fraud gilead intends vigorously defend allegations complaint seeks undetermined amount damages well relief including declaratory injunctive relief defendants lawsuit named numerous lawsuits comparable awp allegations knowledge gilead named lawsuits gilead named served lawsuits comparable awp allegations adverse results could result material damages purported class action complaint filed november united states district court northern district california gilead companys chief executive officer chief financial officer executive vice presidents operations research development senior vice presidents manufacturing research complaint alleges defendants violated federal securities laws specifically sections b securities exchange act rule b securities exchange commission making certain alleged false misleading statements plaintiff seeks unspecified damages behalf purported class purchasers gileads securities period july october similar actions subsequently filed court issued order consolidating lawsuits single action december believe meritorious defenses allegations contained complaint intend defend case vigorously trial date scheduled february court issued order appointing lead plaintiffs action lead plaintiffs march file consolidated complaint december two purported shareholder derivative lawsuits filed individual shareholders behalf gilead directors certain executive officers superior court state california county san mateo alleging among things defendants violated california corporations code breached fiduciary duties owing gilead gilead named nominal defendant plaintiffs seek unspecified damages behalf gilead connection alleged insider trading period july october defendants alleged breach fiduciary duties abuse control waste mismanagement two cases consolidated single action january plaintiffs filed consolidated complaint february trial date scheduled intend take appropriate action defend interests connection litigation also party various legal actions arose ordinary course business believe legal actions material adverse impact business results operations financial position item submission matters vote security holders matters submitted vote securities holders quarter ended december part ii item market registrants common stock related stockholder matters common stock traded nasdaq stock market symbol gild following table sets forth periods indicated high low intraday sale prices per share common stock nasdaq stock market prices represent quotations among dealers without adjustments retail markups markdowns commissions may represent prices actual transactions high low first quarter second quarter third quarter fourth quarter first quarter second quarter third quarter fourth quarter february shares common stock outstanding held approximately stockholders record paid cash dividends common stock since inception anticipate paying foreseeable future december issued million convertible senior notes due december private offering goldman sachs co resold notes qualified institutional investors notes currently convertible total shares common stock per share net proceeds approximately million item selected financial data gilead sciences inc selected consolidated financial data thousands except per share data year ended december consolidated statement operations data total revenues inprocess research development total costs expenses income loss operations gain sale oncology assets provision benefit income taxes income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss amounts per common sharebasic income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss per sharebasic shares used per share calculationbasic amounts per common sharediluted income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss per sharediluted shares used per share calculationdiluted gilead sciences inc selected consolidated financial data continued thousands december consolidated balance sheet data cash cash equivalents marketable securities working capital total assets longterm obligations convertible debt accumulated deficit total stockholders equity gilead completed acquisition net assets triangle aggregate purchase price million approximately million purchase price allocated inprocess research development also recorded income tax benefit million related reduction valuation allowance certain net deferred tax assets sold shares osi common stock recognized loss sale marketable securities million shares partial consideration sale oncology assets completed sale oncology assets related technology osi pharmaceuticals inc recorded nonoperating gain million also recorded nonoperating gain million sale percent interest proligo gilead adopted statement financial accounting standards nos collectively referred sfas accounting derivative instruments hedging activitiesin first quarter change accounted change accounting principle effective first quarter gilead adopted secs staff accounting bulletin sab revenue recognition financial statements change also accounted change accounting principle cash dividends declared paid common stock item managements discussion analysis financial condition results operations executive summary biopharmaceutical company discovers develops commercializes therapeutics advance care patients suffering lifethreatening diseases multinational company revenues six approved products marketing operations ten countries focus research clinical programs antiinfectives currently market viread tenofovir disoproxil fumarate emtriva emtricitabine treatment hiv infection hepsera adefovir dipivoxil treatment chronic hepatitis b infection ambisome amphotericin b liposome injection antifungal agent vistide cidofovir injection treatment cmv retinitis roche markets tamiflu oseltamivir phosphate treatment influenza royalty paying collaborative agreement us december made decision discontinue selling daunoxome daunorubicin citrate liposome injection drug approved treatment kaposis sarcoma seeking add existing portfolio products internal discovery clinical development programs active product acquisition inlicensing strategy acquisition assets triangle pharmaceuticals inc completed january internal discovery activities include identification new molecular targets target screening medicinal chemistry addition currently developing clinical stage products treat hiv infection chronic hepatitis b operating results comparison characterized solid growth key hiv drug viread represent second consecutive year significant increases total product revenues based independent third party data viread become one widely prescribed antiretrovirals class drugs achieving new total prescriptions competing drugs nucleotidenucleoside reverse transcriptase inhibitor nrti market result growth viread sales higher expected ambisome sales controlled spending generated positive cash flow operations last two years increase million million year year growth expect hiv drug sales grow near term although expect slower rate experienced past two years enabling growth increasing importance oncedaily regimens prescribing hiv medications availability viread emtriva acquired triangle provide physicians ability construct daily regimens operating results impacted acquisition assets triangle january completed acquisition expand antiviral pipeline triangle development stage company particular focus potential therapies hiv including aids hepatitis b virus hbv aggregate purchase price million including cash paid million outstanding stock fair value stock options assumed million estimated direct transaction costs million employee related costs million approximately million purchase price allocated process research development represented fair value triangles incomplete research development programs yet reached technological feasibility alternative future use acquisition date result transaction related inprocess research development charge operating loss million versus operating income million acquisition important us compounds acquired also opportunity provided us create coformulation viread emtriva single pill dosed day successful expect coformulated product grow hiv franchise see note consolidated financial statements information triangle acquisitionin december completed sale oncology assets osi pharmaceuticals inc transaction valued million cash osi stock transaction allowed us focus continue strengthen core expertise infectious diseases see note consolidated financial statements information certain prior period amounts reclassified conform current presentation forwardlooking statements risk factors following discussion contains forwardlooking statements involve risks uncertainties please read risk factors affect gilead part factors could cause contribute material differences forwardlooking statements actual results risk factors discussion read conjunction consolidated financial statements notes included elsewhere report critical accounting policies estimates judgments discussion analysis financial condition results operations based upon consolidated financial statements prepared accordance accounting principles generally accepted united states preparation financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosures ongoing basis evaluate estimates including related revenue recognition bad debts inventories accrued clinical preclinical expenses income taxes contingencies base estimates historical experience various marketspecific assumptions believed reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results however may differ significantly estimates believe following critical accounting policies reflect significant judgments estimates used preparation consolidated financial statements record estimated reductions revenue expected returns expired products government rebate programs medicaid reimbursements customer incentives cash discounts prompt payment estimates government rebate programs cash discounts based contractual terms historical utilization rates expectations regarding future utilization rates programs estimates product returns including new products based ongoing analysis industry historical return patterns includes monitoring feedback receive sales force regarding customer use satisfaction purchase thirdparty data assist us monitoring channel inventory levels subsequent prescriptions well new products review long shelf life products sold similar channels monitor activities clinical trials key competitors assess potential impact future sales return expectations necessary expected returns marketed drugs generally low shelf life products ranges months viread months ambisome us conditions become competitive markets served drugs circumstances change may take actions increase product return estimates may offer additional customer incentives would result incremental reduction future revenue time return estimate changed incentives offered example increased reserve government discounts viread sales result review historical utilization rates impact midyear price increase viread could see similar increases future based continued reviews utilization rates potential us price increases viread also maintain allowance doubtful accounts estimated losses resulting inability customers make required payments allowance based analysis several factors including limited historical payment patterns customers individual customer circumstances analysis days sales outstanding customer geographic region review local economic environment potential impact government funding reimbursement practices financial condition customers economic environment operate deteriorate resulting inability make payments additional allowances may required allowance doubtful accounts balance percentage total accounts receivable materially change december december believe allowance doubtful accounts adequate cover anticipated losses current conditions however significant deterioration factors especially respect government funding reimbursement practices european market could materially change expectations result increase allowance doubtful accounts write inventory based historical review quantity raw material bad batches experienced given year expectations production inventory levels also perform quality control reviews individual raw material batches generally maintain inventory reserves based estimated obsolescence risk competition primarily shelf life products long however current assumptions future production inventory levels demand competition change actual market conditions less favorable projected management additional inventory reserves may required could negatively impact product gross margins record accruals estimated clinical preclinical study costs clinical preclinical studies performed third party contract research organizations cros costs significant component research development expenses incurred million million million respectively cro costs accrue costs clinical studies performed cros straightline basis term service period adjust estimates required based upon ongoing review level effort actually incurred cro initially estimate work performed contracts occurs ratably periods expected milestone event total contract completion date expected completion dates estimated based upon terms contracts past experience similar contracts estimates may may match actual services performed organizations determined patient enrollment levels measures activities specified contract result validate accruals quarterly written vendor confirmations detailed reviews activities performed contract based upon results validation processes assess appropriateness accruals make adjustments deem necessary expenses reflect actual effort incurred cros generally significant portion total costs associated start activities trial patient enrollment gilead extensively outsources clinical trial activities usually performs small portion startup activities inhouse result cros typically perform total startup activities trials including document preparation site identification screening preparation prestudy visits training program management budgeted basis costs typically total contract value actual basis percentage range significantly wider many contracts either expanded contracted scope compared original budget startup costs particular trial change significantly startup costs usually occur within months contract established milestone event driven nature remaining activities related costs patient monitoring administration generally occur ratably throughout life individual contract study contracts negotiated fixed price vary length six months single dose phase study two years complex phase study average length contract upper end range order provide long term safety efficacy data support commercial launches viread hepsera emtriva throughdecember understated overstated activity levels particular study material adjustment required material cro contracts terminable us upon written notice gilead generally liable actual effort expended cro point time contract regardless payment status amounts paid advance services performed refunded contract terminated however management receive complete accurate information vendors underestimated activity levels associated study given point time would record additional potentially significant research development expenses future periods develop income tax provision including deferred tax assets liabilities based significant management judgment record valuation allowance reduce deferred tax assets amount likely realized consider future taxable income ongoing tax planning strategies historical financial performance assessing need valuation allowance determined would able realize certain deferred tax assets related valuation allowance adjustment deferred tax asset would increase income period determination made adjustment made fourth quarter determined likely certain deferred tax assets realized therefore released related valuation allowance resulted income tax benefit approximately milion likewise determine would able realize part deferred tax asset future adjustment deferred tax asset would charged income period determination made evaluate realizibility deferred tax assets quarterly basis future effective tax rate may affected factors changes tax laws rates changes interpretation laws overall changes future levels earnings research development capital spending management discussed development selection critical accounting policies audit committee gileads board directors audit committee reviewed disclosure presented relating results operations total revenues total revenue million million million included total revenue net product sales royalty revenue contract revenue including revenue research development rd manufacturing collaborations product sales consisted following thousands product sales change change viread ambisome total product sales product sales increased compared primarily due significant increases sales viread hiv approved sale us october european union february since become antiretroviral therapy widely prescribed physicians significant percentage product sales continue denominated foreign currencies prior hedge exposure impact fluctuating foreign exchange rates forecasted sales january began use forward contracts hedge percentage forecasted international sales primarily denominated euro currency reduces eliminate fluctuations sales due changes foreign currency exchange rates losses revenue hedges reduced product revenues million million sales viread total product sales compared total product sales total product sales viread sales million us sales increase versus million international sales increase versus continued market expansion viread expect viread sales grow approximately range million million experienced significant fluctuations us distribution channel inventory levels due speculative purchasing major wholesalers result experienced increased quarter quarter sales volatility purchasing patterns enacted certain policies reduce type purchasing discussions key wholesalers expect continue experience sales volatility foreseeable future prior revenues primarily derived sales ambisome represented total product sales total product sales ambisome sales million higher due favorable currency environment compared volume basis ambisome sales europe decreased compared due increasing competition excluding impact foreign currencies relative us dollar ambisome sales grew increase sales compared primarily due volume sales increases europe offset declining sales us expected increase competition expect ambisome sales lower range million million royalty revenue recorded royalty revenue million compared million million threeyear period significant source royalty revenue sales ambisome us fujisawa copromotion arrangement us royalty revenue fujisawa million compared million million also recorded royalty revenue million million million related sales tamiflu began recognizing royalties tamiflu first quarter june roche received european regulatory approval tamiflu treatment influenza adults children prevention adolescents adults difficult estimate third party product sales record royalty revenue one quarter arrears due lag reporting royalties related severe flu epidemic us fourth quarter recorded first quarter contract revenue total contract revenue million compared million million primary source contract revenue licensing selex process patent estate archemix due collectibility concerns recognized cash received thisprovided contract revenue million million roche made milestone payments million european prophylaxis treatment approvals tamiflu made million milestone payment relating development tamiflu rd collaboration agreement december entitled additional milestone payments million upon roche achieving certain developmental regulatory milestones april gilead gsk entered licensing agreement providing gsk rights commercialize hepsera antiviral treatment chronic hepatitis b asia latin america certain territories agreement gilead retained rights hepsera us canada eastern western europe australia new zealand gsk received exclusive rights develop hepsera solely treatment chronic hepatitis b territories significant include china korea japan taiwan gsk paid us upfront licensing fee million may pay additional million upon achievement gsk certain regulatory development commercial milestones million million received us approval hepsera september million received canadian approval hepsera august gsk also pay us royalty net sales hepsera gsk territories gsk full responsibility development commercialization hepsera gsks territories million upfront fee million approval milestone fees recorded deferred revenue total million million recognized contract revenue respectively million balance deferred revenue december amortized contract revenue period remaining obligations agreement approximately years december completed sale oncology assets osi date received million cash million osi stock sale agreement entitled additional payments osi million either cash combination cash osi stock osi reaches certain development milestones nx advanced oncology product candidates sold osi related manufacturing agreement produce nx gs l two liposomal products included sale manufacturing facility san dimas california recognized million million respectively contract revenue manufacturing agreement october entered agreement archemix corporation relating selex technology agreement gave archemix exclusive rights selex process including therapeutic commercial applications extent already licensed preexisting agreements archemix paid us million million recorded net amounts million million contract revenue respectively required license agreement ulehi paid million million payments ulehi also received warrant purchase shares archemix common stock value material required license agreement ulehi transferred warrant ulehi time since transferred remainder warrant ulehi march entered agreement eyetech pharmaceuticals inc relating proprietary aptamer eye currently known macugen currently phase clinical trials macugen inhibitor vascular endothelial growth factor vegf known play role development certain ophthalmic diseases terms agreement eyetech received worldwide rights therapeutic uses macugen product successfully commercialized eyetech pay us royalties worldwide sales product eyetech also responsible research development costs provided clinical supplies product eyetech march received million upfront licensing fee eyetech april recognized revenue ratably oneyear supply agreement period accordingly million license fee recorded contract revenue million recognized revenue also entitled additional cash payments eyetech million eyetech reaches certain macugen development milestones additionally received warrant purchase shares eyetech series b convertible preferred stock exercisable price per share price stock issued investors january eyetech completed initial public offering intend exercise warrant shares common stock sell shares subject day lockup period fair value warrant adjusted first quarter result eyetech public offering cost goods sold following table indicates cost goods sold thousands change change cost goods sold substantially increase year year period attributed increases volume viread sold product launched us late third quarter gross margins product gross margins compared improvement primarily driven product mix viread higher margin product contributed significantly net product sales succeeding year movements foreign currency exchange rates also impact gross margins price products currency country products sold significant majority manufacturing costs us dollars example increase value foreign currencies relative us dollar positively impact gross margins since manufacturing costs remain approximately revenues translated us dollars increase gross margins positively impacted weakening us dollar gross margins negatively impacted factors since forward contracts used hedge percentage forecasted international sales reduce impact changes foreign currency exchange rates gross margins except potential impact unpredictable uncontrollable changes exchange rates relative us dollar mix product sales viread hepsera ambisome expect gross margins remain relatively stable compared research development expenses rd expenses total costs expenses excluding purchased inprocess research development expense total rd expenses million compared million million major components rd expenses consist personnel costs including salaries benefits clinical studies performed contract research organizations materials supplies overhead allocations consisting various support facilities related costs rd activities also separated three main categories research clinical development pharmaceutical development research costs typically consist preclinical toxicology work clinical development costs include phase clinical trials well expanded access programs pharmaceutical development costs consist product formulation chemical analysis following table breaks research development expenses major components thousands change change research clinical development pharmaceutical development oncology divested total million increase rd spending versus attributable increased headcount clinical trials associated development emtriva coformulation viread emtriva addition settled contractual dispute vendor resulted reimbursement us million recorded research development expense expect rd expenses approximately million million approximately higher expenses due primarily costs associated development fixeddose combination viread emtriva million decrease rd spending compared primarily due reduction expenses associated clinical program viread approved fda sale us october elimination expenses associated oncology program result sale program osi december additionally recognized expense million million upfront license fee paid cubist pharmaceuticals related european licensing agreement daptomycin also known cidecin signed january upon termination agreement september recorded million rd expense represented remaining unamortized asset related preclinical oral formulation daptomycin industry reports indicate biopharmaceutical company generally takes years average years research develop bring market new prescription medicine us averages generally consistent projects develop internally although recent product development timelines accelerated basis drug development us process includes several steps defined fda process begins filing ind successful allows opportunity clinical study potential new medicine clinical development typically involves three phases study phase generally accounts average seven years drugs total development time significant costs associated clinical development phase trials tend longest largest studies conducted drug development process currently products development phase studies successful development products highly uncertain completion dates rd expenses vary significantly product difficult predict even successful development fda approval product undertake additional studies try expand products label market potential complete discussion risks uncertainties associated completing development products see risk factors affect gilead section item selling general administrative expenses following table highlights selling general administrative expenses thousands change change selling general administrative increase expenses compared primarily due global sales marketing efforts including expansion us european sales forces increased infrastructure investments required support growth business increase expenses compared primarily due global sales marketing efforts including expansion us european sales forces support commercial launches viread hepsera expect sga expenses approximately million million higher levels primarily due increase marketing activities associated continued promotion viread emtriva hepsera ambisome inprocess research development connection acquisition net assets triangle completed january recorded inprocess research development expenses million first quarter charge due triangles incomplete research development programs yet reached technological feasibility alternative future use acquisition date remaining efforts completion triangles research development projects primarily consist clinical trials cost length success extremely difficult predict numerous risks uncertainties exist could prevent completion development including ability enroll patients clinical trials possibility unfavorable results clinical trials risk failing obtain fda regulatory body approvals feedback regulatory authorities results clinical trials might require modifications delays later stage clinical trials additional trials performed certain emtricitabine treatment chronic hepatitis b purchased triangle approved us european union whether marketing approvals significant limitations use terminated rights respect potential products acquired acquisition triangle also yet approval fixeddose combination product containing tenofovir df emtricitabine future discussions regulatory agencies determine amount data needed timelines review may differ materially current projections acquired products development may never successfully commercialized emtriva example product many similarities existing products result may difficult successfully penetrate market achieve significant revenues addition emtricitabine treatment chronic hepatitis b faces significant uncertainties associated pricing efficacy cost produce may successfully resolved result may make strategic decision discontinue development product clevudine amdoxovir believe commercialization difficult relative opportunities pipeline programs completed timely basis prospects future revenue growth would adversely impacted value acquired inprocess research development determined estimating related future net cash flows using present value risk adjusted discount rate discount rate significant assumption based estimated weighted average cost capital adjusted upward risks associated projects acquired projected cash flows acquired projects based estimates revenues operating profits related projects considering stage development potential product acquired time resources needed complete development approval product life potential commercialized product associated risks including inherent difficulties uncertaintiesin developing drug compound including obtaining fda regulatory approvals risks related viability potential alternative treatments future target markets asset impairment recorded asset impairment charge million certain longlived assets primarily leasehold improvements manufacturing laboratory equipment noncash charge driven decision december terminate liposomal research development activities san dimas discontinue daunoxome product line impairment based analysis undiscounted cash flows generated affected assets compared carrying value carrying value exceeded related estimated undiscounted cash flows wrote carrying value long lived assets estimated fair value gain sale oncology assets december completed sale oncology assets pipeline clinical stage oncology products related intellectual property well boulder colorado operations including clinical research drug development personnel infrastructure facilities osi pipeline clinical candidates includes nx liposomal lurtotecan gs nucleoside analogue gs l liposomal thymidylate synthase inhibitor closing date received million cash osi common stock valued approximately million recorded nonoperating gain million income taxes million fourth quarter result transaction loss sale marketable securities july sold remaining shares osi common stock approximately million shares partial consideration sale oncology assets osi december time recorded fair market value approximately million connection sale remaining shares recognized nonoperating loss approximately million year ended december gain sale unconsolidated affiliate august sold percent interest proligo llc proligo degussa corporation million cash proligo joint venture us skw americas inc focused manufacturing oligonucleotides skw americas subsidiary degussa corporation held remaining percent proligo proceeds net investment proligo reflected million gain sale unconsolidated affiliate interest income net recorded interest income million compared million million decrease compared attributable significant decline interest rates lower average cash balance due acquisition net assets triangle purchase foster city campus partially offset positive cash flow operations decrease compared attributable significant decline interest rates partially offset higher average cash balance due positive cash flow operations proceeds sale oncology assets osi interest income depend principally upon prevailing interest rates control level cash cash equivalent marketable securities balances interest expense incurred interest expense million compared million million significant increase due full year interest million convertible senior notes issued december interest expense consisted primarily interest million convertible subordinated notes converted common stock december expect interest expense decrease compared primarily due redemption million convertible subordinated notes december provision benefit income taxes provision benefit income taxes million million million respectively benefit includes reversal valuation allowance certain deferred tax assets december concluded likely would realize portion benefit related deferred tax assets accordingly reduced valuation allowance assets recorded tax benefit million recognition deferred tax assets impact current period cash flows recognition deferred tax assets increased reported earnings per share due resulting benefit recorded statement operations reduction valuation allowance partially offsetting tax benefit recorded income tax expense associated income earned foreign subsidiaries foreign losses lower rates nontax deductibility purchased inprocess research development charge significant net operating losses reducing us liability excluding benefit relating reversal valuation allowance write purchased inprocess research development effective tax rate expect effective tax rate range full year reflecting normalized tax rate going forward income tax expense primarily associated income earned foreign subsidiaries significant net operating losses reduced us tax liability significant increases income tax expense resulted principally gain sale oncology assets osi recorded approximately million federal state alternative minimum taxes provision reduced change us income tax law law allowed net operating loss carryforward deductions offset alternative minimum taxable income resulting reduction us income tax recorded previous years million equity loss unconsolidated affiliate recorded million equity loss unconsolidated affiliate proligo sold percent interest august cumulative effect change accounting principle adopted sfas accounting derivative instruments hedging activities resulted cumulative effect change accounting principle million see note consolidated financial statements discussionliquidity capital resources cash cash equivalents marketable securities totaled million december million december decrease million primarily due acquisition triangle net cash impact million purchase foster city campus million major sources uses cash included net cash provided operations million proceeds issuances stock employee stock plans million partially offset additional capital expenditures million working capital december million compared million december significant changes working capital included million increase accounts receivable million increase inventory million increase current deferred tax assets accounts receivable increase primarily due increased sales viread us europe million increase inventory primarily due increase purchase raw materials production viread inventory meet increasing sales demand million increase current deferred tax assets due reversal valuation allowance certain net deferred tax assets million increase accounts payable primarily due increases raw material purchases support viread sales growth significant changes current liabilities included million increase accrued liabilities significant components million increase accrued liabilities exclusive assumed liabilities associated acquisition net assets triangle consist million increase accrued liabilities million increase accrued compensation employee benefits partially offset million decrease accrued clinical preclinical expenses million increase accrued liabilities primarily due medicaid rebate obligations associated higher sales viread increase income taxes payable increase recorded liability associated fair value forward currency contracts million increase accrued compensation primarily due increased bonus accruals expansion sales force million decrease accrued clinical preclinical expenses primarily due decreasing activity associated clinical trial programs viread hepsera addition purchase foster city campus made capital expenditures million compared million million expenditures primarily facilities improvements accommodate growth well laboratory manufacturing equipment capital expenditures related research development million spent million spent million spent expect capital spending million million due increased infrastructure needs higher rd spending associated pilot plant constructing foster city facilities december issued million convertible senior notes due december private offering notes currently convertible total shares gilead common stock per share conversion price higher gileads common stock price notes issuance date notes redeemable whole part option time june specified redemption prices plus accrued interest debt issuance costs million incurred connection issuance notes recorded noncurrent assets amortized interest expense straightline basis contractual term notes december issued million convertible subordinated notes due december private offering notes convertible total shares gilead common stock per share conversion price higher gileads common stock price notes issuance date gilead called million convertible subordinated notes redemption november converted gilead common stock december upon conversion million remaining balance related debt issuance costs reclassified additional paid capital believe existing capital resources supplemented cash generated operations adequate satisfy capital needs foreseeable future future capital requirements depend many factors including commercial performance current future products progress scope research development efforts including preclinical studies clinical trials cost timing outcome regulatory reviews expansion sales marketing capabilities administrative expenses costs associated noprofit global access program least developed nations possibility acquiring manufacturing capabilities office facilities possibility acquiring companies new products establishment additional collaborative relationships companies may future require additional funding could form proceeds equity debt financings universal shelf registration filing december potential issuance million securities additional collaborative agreements corporate partners funding required assure available favorable terms subsidiaries established variety subsidiaries various countries purpose conducting business locations subsidiaries consolidated financial statements special purpose entities unconsolidated financial statements also involved nonexchange traded commodity contracts accounted fair value commercial commitments related parties except employee loans contractual obligations contractual obligations form capital operating leases notes payable raw material supply arrangements clinical research organization contracts following table summarizes contractual obligations thousandspayments due period less one contractual obligations total year years years years longterm debt obligations capital lease obligations operating lease obligations capital commitments inventory purchase obligations clinical trials total december firm capital project commitments approximately million related chemical development pilot plant currently construction foster city facility budgeted capital expenditures significantly higher anticipate increasing capital spending future years december firm commitments purchase inventoryrelated materials amounts disclosed represent minimum purchase requirements actual purchases may differ significantly amounts december several clinical studies various clinical trial phases significant expenditures contract research organizations although contracts cancelable generally cancelled contracts amounts reflect commitments based existing contracts reflect future modifications existing contracts anticipated potential new contracts recent accounting pronouncements january fasb issued fasb interpretation fin consolidation variable interest entities interpretation arb fin requires certain variable interest entities consolidated primary beneficiary entity equity investors entity characteristics controlling financial interest sufficient equity risk entity finance activities without additional subordinated financial support parties fin effective immediately new variable interest entities created acquired january create acquire new variable interest entities january variable interest entities created acquired prior february provisions fin amended must applied end first interim annual period ending march adoption fin material impact consolidated financial statements item quantitative qualitative disclosures market risk foreign currency exchange risk operations include manufacturing sales activities us well sales activities europe australia result financial results could significantly affected factors changes foreign currency exchange rates weak economic conditions foreign markets distribute products operating results exposed changes exchange rates us dollar various foreign currencies significant euro british pound australian dollar us dollar strengthens currencies relative value sales made respective foreign currency decreases conversely us dollar weakens relative amounts sales increase overall net receiver foreign currencies therefore benefit weaker us dollar adversely affected stronger us dollar relative foreign currencies transact significant amounts business mitigate impact changes currency exchange rates cash flows foreign currency sales transactions enter foreign exchange forward contracts hedge foreign currencydenominated accounts receivable additionally mitigate impact currency rate fluctuations cash outflows certain foreign currencydenominated raw materials purchases enter foreign exchange forward contracts hedge foreign currencydenominated accounts payable significant percentage product sales denominated foreign currencies increases value us dollar foreign currencies past reduced future may reduce us dollar return sales negatively impact financial condition prior hedge exposure impact fluctuating foreign exchange rates forecasted sales january began use forward contracts hedge percentage forecasted international sales primarily denominated euro currency following table summarizes notional amounts average currency exchange rates fair values open foreign exchange forward contracts december contracts maturities one year less average rates stated terms amount foreign currency per us dollar fair values represent estimated settlement amounts december notional amounts fair values us dollars thousands fair value currency notional amount average rate december british pound euro total notional amount million fair value million open foreign exchange forward contracts december compares total notional amount million fair value million open foreign exchange forward contracts december significant increase outstanding contracts attributed decision expand time horizon include three months twelve months hedging forecasted international sales decision made due growth international business increasing fluctuations exchange rates primarily euro interest rate risk portfolio availableforsale investment securities fixedrate liabilities create exposure interest rate risk respect investment portfolio adhere investment policy requires us limit amounts invested securities based duration industry group investment type issuer except securities issued us government goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return following table summarizes expected maturities average interest rates interestbearing assets fixedrate liabilities december dollars thousands fair value years ending december december thereafter total assets availableforsale securities average interest rate liabilities longterm obligations including current portion average interest rate convertible senior debentures interest rate longterm obligations consist capital leases operating leases net noncancelable subleases interest portion payments due included international credit risk accounts receivable balance december million compared million december growth primarily due higher product sales viread us europe certain countries payments typically slow primarily greece spain portugal italy accounts receivable balances significant cases slow payment practices reflect pace governmental entities reimburse customers turn may increase financial risk related certain customers sales customers countries tend relatively slow paying past increased future may increase average length time accounts receivable outstanding december past due accounts receivable greece spain portugal italy totaled approximately million approximately million days past due december past due receivables countries million approximately million days past due date experienced significant losses respect collection accounts receivable believe accounts receivable balances reflected consolidated balance sheet including due customers four countries collectible perform credit evaluations customers financial condition generally required collateral item financial statements supplementary data financial statements required item set forth beginning report incorporated herein reference item changes disagreements accountants accounting financial disclosure none item controls procedures evaluation disclosure controls procedures evaluation december carried supervision participation management including chief executive officer chief financial officer effectiveness design operation disclosure controls procedures defined sec rules controls procedures company designed ensure information required disclosed company reports files securities exchange act exchange act recorded processed summarized reported within required time periods based upon evaluation chief executive officer chief financial officer concluded disclosure controls procedures effective b changes internal controls financial reporting management including chief executive officer chief financial officer evaluated changes internal control financial reporting occurred quarter ended december concluded change quarter materially affected reasonably likely materially affect internal control financial reporting part iii item directors executive officers registrant information required item concerning directors executive officers incorporated reference sections definitive proxy statement filed sec pursuant regulation connection annual meeting proxy statement headings nominees executive officers board directors audit committee compliance section securities exchange act item executive compensation information required item incorporated reference sections proxy statement headings executive compensation compensation committee reportitem security ownership certain beneficial owners management information required item incorporated reference section proxy statement heading security ownership certain beneficial owners management item certain relationships related transactions information required item incorporated reference sections proxy statement headings compensation committee interlocks insider participation certain transactions executive compensation item principal accountant fees services information required item incorporated reference sections definitive proxy statement filed sec pursuant regulation connection annual meeting proxy statement headings independent accountants part iv item exhibits financial statement schedules reports form k following documents filed part index list financial statements report ernst young llp independent auditors audited consolidated financial statements consolidated balance sheets consolidated statements operations consolidated statement stockholders equity consolidated statements cash flows notes consolidated financial statements schedule ii included report schedules omitted required required information included financial statements notes thereto exhibits following exhibits filed herewith incorporated reference exhibit exhibit description footnote number document asset purchase agreement registrant osi pharmaceuticals inc dated november agreement plan merger among registrant simbolo acquisition sub inc wholly owned subsidiary registrant triangle pharmaceuticals inc dated december amended restated certificate incorporation registrant amended bylaws registrant amended restated march reference made exhibit exhibit amended restated rights agreement dated october registrant chasemellon shareholder services llc agreement plan merger dated february among registrant gazelle acquisition sub inc nexstar pharmaceuticals inc indenture dated december registrant chase manhattan bank trust company national association including therein forms notes indenture dated december registrant jp morgan trust company national association including therein forms notes registration rights agreement dated december registrant goldman sachs co first amendment amended restated rights agreement dated october registrant mellon investor services llc form indemnity agreement entered registrant directors executive officers form employee proprietary information invention agreement entered registrant certain officers key employees registrants incentive stock option plan related agreements registrants supplemental stock option plan related agreements registrants employee stock purchase plan amended march registrants stock option plan amended restated april amended january amended january form nonqualified stock option issued certain executive officers directors vintage park research development net lease registrant vintage park associates dated march premises located b lakeside drive foster city california related addendum exhibits amendments letter agreement dated september registrant iocbrega exhibits certain confidential information omitted amendment agreement dated october registrant iocbrega related license agreements exhibits certain confidential information omitted amendment agreement dated december registrant iocbrega loan agreement dated october among registrant mark l perry melanie p pea registrants nonemployee directors stock option plan amended january amended january amendment vintage park research development lease registrant wcb seventeen limited partnership dated june premises located b lakeside drive foster city california license supply agreement registrant pharmacia upjohn sa dated august certain confidential information omitted development license agreement registrant f hoffmannla roche ltd hoffmannla roche inc dated september certain confidential information omitted nexstar pharmaceuticals incs incentive stock plan adopted february amended nexstar pharmaceuticals incs director option plan adopted july vestar inc stock option plan lease dated march vestar inc majestic realty co patrician associates inc amendment thereto amendment thereto dated june third amendment dated january majestic realty co patrician associates inc registrant lease dated march vestar inc majestic realty co patrician associates inc assignment royalty agreement dated december effective june vestar inc city hope national medical center license agreement effective august vestar inc regents university california agreement fujisawa usa inc vestar inc dated august amendment thereto dated may amendment agreement fujisawa usa inc vestar inc dated april fujisawa usa inc vestar inc certain confidential information omitted amendment agreement fujisawa usa inc registrant dated march agreement fujisawa usa inc vestar inc dated august lease dated april vestar inc majestic realty co patrician associates inc first amendment lease dated april majestic realty co patrician associates inc vestar inc amending lease dated april majestic realty co patrician associates inc vestar inc license distribution agreement dated september sumitomo pharmaceuticals co ltd nexstar pharmaceuticals inc certain confidential information omitted settlement agreement dated august among nexstar pharmaceuticals inc fujisawa usa inc liposome company inc certain confidential information omitted amendment dated april sumitomo pharmaceuticals co ltd nexstar pharmaceuticals inc license distribution agreement dated september sumitomo nexstar pharmaceuticals inc corporate plan retirement select planbasic plan document corporate plan retirement select planadoption agreement addendum gilead sciences inc deferred compensation plan licensing agreement dated april gilead world markets limited glaxo group limited employment agreement dated july gilead sciences inc sharon surreybarbari triangle pharmaceuticals inc stock incentive plan option agreement triangle pharmaceuticals inc daniel g welch dated august license agreement among triangle pharmaceuticals inc emory university university georgia research foundation inc compound amdoxovir dapd dated march license agreement triangle pharmaceuticals inc emory university coviracil ftc dated april exclusive license agreement among triangle pharmaceuticals inc glaxo group limited wellcome foundation limited glaxo wellcome inc emory university dated may settlement agreement among triangle pharmaceuticals inc emory university dr david w barry glaxo wellcome plc glaxo wellcome inc glaxo group limited wellcome foundation limited dated may first amendment license agreement triangle pharmaceuticals inc emory university dated may first amendment license agreement among triangle pharmaceuticals inc emory university university georgia research foundation inc dated july second amendment license agreement triangle pharmaceuticals inc emory university dated july supply manufacturing agreement triangle pharmaceuticals inc abbott laboratories dated july settlement exclusive license agreement among triangle pharmaceuticals inc shire biochem inc shire pharmaceuticals group plc emory university university georgia research foundation dated august second amendment license agreement among triangle pharmaceuticals inc emory university university georgia research foundation inc dated august manufacturing supply agreement gilead world markets ltd ppgsipsy sas entered january gilead sciences inc severance plan adopted effective january third amendment license agreement triangle pharmaceuticals inc emory university dated may lease agreement dated june th registrant gra associates limited llc premises located university drive durham north carolina master clinical commercial supply agreement dated january among gilead world markets ltd gilead sciences inc patheon inc toll manufacturing agreement dated august among gilead world markets ltd gilead sciences inc altana pharma oranienburg gmbh licensing agreement dated march amended may december april gilead sciences inc eyetech pharmaceuticals inc amendment licensing agreement dated may eyetech pharmaceuticals inc gilead sciences inc amendment licensing agreement dated december eyetech pharmaceuticals inc gilead sciences inc amendment licensing agreement dated august eyetech pharmaceuticals inc gilead sciences inc amendment dated may licensing agreement dated april glaxo group limited gilead world markets limited amendment dated january licensing agreement dated april glaxo group limited gilead world markets limited subsidiaries registrant consent ernst young llp independent auditors power attorney reference made signature section certification section certification section certification filed exhibit registrants annual report fiscal year ended december incorporated herein reference filed exhibit registrants quarterly report form q quarter ended december incorporated herein reference filed exhibit nexstar pharmaceuticals incs quarterly report form q quarter ended june incorporated herein reference filed exhibit registrants current report form k filed october incorporated herein reference filed exhibit registrants registration statement form amended incorporated herein reference filed exhibit registrants quarterly report form q quarter ended september incorporated herein reference filed exhibit registrants annual report fiscal year ended march incorporated herein reference filed exhibit registrants quarterly report form q quarter ended june incorporated herein reference filed exhibit registrants quarterly report form q quarter ended september incorporated herein reference filed exhibit registrants current report form k filed march incorporated herein reference filed exhibit nexstar pharmaceuticals incs fiscal year ended december incorporated herein reference filed exhibit nexstar pharmaceuticals incs fiscal year ended december incorporated herein reference filed exhibit nexstar pharmaceuticals incs form q quarterly period ended september incorporated herein reference filed exhibit nexstar pharmaceuticals incs fiscal year ended december incorporated herein reference filed march exhibit nexstar pharmaceuticals incs registration statement form file incorporated herein reference filed exhibit nexstar pharmaceuticals incs form q quarterly period ended september incorporated herein reference filed exhibit nexstar pharmaceuticals incs form q quarter ended june incorporated herein reference filed exhibit registrants fiscal year ended december incorporated herein reference filed exhibit registrants registration statement form amended incorporated herein reference filed exhibit registrants fiscal year ended december incorporated herein reference filed exhibit registrants current report form k filed january incorporated herein reference filed exhibit registrants quarterly report form q quarter ended june incorporated herein reference filed exhibit registrants quarterly report form q quarter ended september incorporated herein reference filed exhibit registrants fiscal year ended december incorporated herein reference filed exhibit registrants current report form k filed december incorporated herein reference filed exhibit registrants registration statement form filed january incorporated herein reference filed exhibit registrants registration statement form filed january incorporated herein reference filed exhibit triangle pharmaceuticals incs registration statement form amended incorporated herein reference filed exhibit triangle pharmaceuticals incs quarterly report form q quarter ended september incorporated herein reference filed exhibit triangle pharmaceuticals incs quarterly report form q quarter ended september incorporated herein reference filed exhibit triangle pharmaceuticals incs current report form k filed september incorporated herein reference filed exhibit triangle pharmaceuticals incs quarterly report form q quarter ended september incorporated herein reference filed exhibit registrants current report form k filed october incorporated herein reference filed exhibit registrants quarterly report form q quarter ended march incorporated herein reference filed exhibit registrants quarterly report form q quarter ended june incorporated herein reference filed exhibit registrants fiscal year ended december incorporated herein reference certain confidential portions exhibit omitted means marking portions asterisk mark exhibit filed separately secretary sec without mark pursuant registrants application requesting confidential treatment rule b securities exchange act b reports form k october company filed form k announcing earnings company third quarter nine months ended september october company filed form k announcing board directors approved amendment companys amended restated rights agreement originally adopted november amended restated october november company filed form k announcing purported class action complaint filed november united states district court northern district california company companys chief executive officer chief financial officer executive vice presidents operations research development senior vice presidents manufacturing research gilead sciences inc consolidated financial statements years ended december contents report ernst young llp independent auditors audited consolidated financial statements consolidated balance sheets consolidated statements operations consolidated statement stockholders equity consolidated statements cash flows notes consolidated financial statements report ernst young llp independent auditors board directors stockholders gilead sciences inc audited accompanying consolidated balance sheets gilead sciences inc december related consolidated statements operations stockholders equity cash flows three years period ended december audits also included financial statement schedule listed item annual report financial statements schedule responsibility management gilead sciences inc responsibility express opinion financial statements schedule based audits conducted audits accordance auditing standards generally accepted united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements audit also includes assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audits provide reasonable basis opinion opinion financial statements referred present fairly material respects consolidated financial position gilead sciences inc december consolidated results operations cash flows three years period ended december conformity accounting principles generally accepted united states also opinion related financial statement schedule considered relation basic financial statements taken whole presents fairly material respects information set forth therein discussed note consolidated financial statements effective january company changed method accounting derivative instruments hedging activities ernst young llp palo alto california january gilead sciences inc consolidated balance sheets thousands except per share amounts december assets current assets cash cash equivalents marketable securities accounts receivable net allowance doubtful accounts december december note receivable triangle pharmaceuticals inc inventories deferred tax assets prepaid expenses total current assets property plant equipment net noncurrent deferred tax assets noncurrent assets liabilities stockholders equity current liabilities accounts payable accrued clinical preclinical expenses accrued compensation employee benefits accrued liabilities deferred revenue longterm obligations due within one year total current liabilities longterm deferred revenue longterm obligations due one year convertible senior debt convertible subordinated debt commitments contingencies stockholders equity preferred stock par value per share issuable series shares authorized none outstanding common stock par value per share shares authorized shares issued outstanding december december respectively additional paidin capital accumulated comprehensive income deferred compensation accumulated deficit total stockholders equity see accompanying notes gilead sciences inc consolidated statements operations thousands except per share amounts year ended december revenues product sales royalty revenue contract revenue total revenues costs expenses cost goods sold research development selling general administrative inprocess research development asset impairment total costs expenses income loss operations gain sale oncology assets gain sale unconsolidated affiliate loss sale marketable securities interest income net interest expense income loss provision benefit income taxes equity loss unconsolidated affiliate cumulative effect change accounting principle provision benefit income taxes equity loss unconsolidated affiliate income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss amounts per common sharebasic income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss per sharebasic shares used per share calculationbasic amounts per common sharediluted income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss per sharediluted shares used per share calculationdiluted see accompanying notes gilead sciences inc consolidated statement stockholders equity thousands accumulated additional comprehensive total common stock paidin income deferred accumulated stockholders balance dece mber h u nt c p l lo com pens ion e f c e q u net income unrealized gain available forsale securities net foreign currency translation adjustment unrealized gain cash flow hedges net comprehensive income employee stock purchase plan option exercises net tax benefits employee stock plans amortization deferred compensation compensatory stock transactions balance december net income unrealized loss available forsale securities net foreign currency translation adjustment unrealized gain cash flow hedges net comprehensive income employee stock purchase plan option exercises net tax benefits employee stock plans compensatory stock transactions balance december net loss unrealized loss available forsale securities net foreign currency translation adjustment unrealized loss cash flow hedges net comprehensive loss conversion convertible subordinated debt acquisition triangle pharmaceuticals inc employee stock purchase plan option exercises net tax benefits employee stock plans amortization deferred compensation compensatory stock transactions balance december see accompanying notes gilead sciences inc consolidated statements cash flows thousands year ended december operating activities net income loss adjustments reconcile net income loss net cash provided used operating activities depreciation amortization purchased inprocess research development asset impairment net effect change accounting principle gain sale oncology assets gain sale unconsolidated affiliate loss sale marketable securities equity loss unconsolidated affiliate net movement provision doubtful accounts deferred tax assets tax benefits employee stock plans noncash transactions changes operating assets liabilities accounts receivable inventories prepaid expenses assets accounts payable accrued liabilities deferred revenue net cash provided used operating activities investing activities purchases marketable securities proceeds sales maturities marketable securities acquisition triangle net assets net cash acquired acquisition real estate capital expenditures issuance note triangle proceeds sale oncology assets proceeds sale unconsolidated affiliate net cash provided used investing activities financing activities proceeds issuances common stock repayments longterm debt proceeds issuance convertible senior notes net issuance costs net cash provided financing activities effect exchange rate changes cash net increase decrease cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year supplemental disclosure cash flow information interest paid income taxes paid noncash investing financing activities osi common stock received upon sale oncology assets common stock issued upon conversion debt reclassification deferred debt issuance costs additional paidin capital upon conversion subordinated debt see accompanying notes gilead sciences inc notes consolidated financial statements december organization summary significant accounting policies overview gilead incorporated delaware june biopharmaceutical company discovers develops commercializes therapeutics advance care patients suffering lifethreatening diseases multinational company revenues six approved products marketing operations ten countries focus research clinical programs antiinfectives currently market viread tenofovir disoproxil fumarate emtriva emtricitabine treatment hiv infection hepsera adefovir dipivoxil treatment chronic hepatitis b infection ambisome amphotericin b liposome injection antifungal agent vistide cidofovir injection treatment cmv retinitis roche markets tamiflu oseltamivir phosphate treatment influenza royalty paying collaborative agreement us seeking add existing portfolio products internal discovery clinical development programs active product acquisition inlicensing strategy acquisition net assets triangle pharmaceuticals inc completed january internal discovery activities include identification new molecular targets target screening medicinal chemistry addition currently developing clinical stage products treat hiv infection chronic hepatitis b accompanying consolidated financial statements include accounts gilead wholly majorityowned subsidiaries significant intercompany transactions eliminated certain prior period amounts reclassified consistent current year presentation stock split february march gilead completed twoforone stock splits effected form stock dividend stockholders record february february respectively accordingly share per share amounts periods presented reflect splitschange accounting principle gilead adopted statement financial accounting standards sfas nos collectively referred sfas accounting derivative instruments hedging activitiesin first quarter change accounted change accounting principle see note critical accounting policies estimates judgments preparation consolidated financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosure assets liabilities ongoing basis management evaluates estimates including related revenue recognition bad debts inventories income taxes accrued clinical preclinical expenses contingencies base estimates historical experience various market specific relevant assumptions believed reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results may differ significantly estimates gilead sciences inc notes consolidated financial statements continued december organization summary significant accounting policies continued revenue recognition recognize revenue product sales persuasive evidence arrangement exists delivery customer occurred price fixed determinable collectibility reasonably assured provide customers general right product return however accept returns products us expired one year expiration products deemed damaged defective received customer upon recognition revenue product sales provisions made expected returns expired products government reimbursements customer incentives cash discounts prompt payment estimates government reimbursements cash discounts based contractual terms expectations regarding utilization rates programs estimates product returns including new products based ongoing analysis industry historical return patterns well purchase third party data assist company monitoring channel inventory levels subsequent prescriptions contract revenue research development recorded performance occurs earnings process completed based performance requirements contract nonrefundable contract fees performance obligations exist continuing involvement gilead recognized earlier payments received collection assured revenue nonrefundable upfront license fees milestone payments continue involvement development collaboration obligation supply product recognized performance occurs performance obligations completed accordance specific terms gileads obligations contract revenue recognized manufacturing obligation fulfilled ratably development period period manufacturing obligation appropriate revenue associated substantive performance milestones recognized based upon achievement milestones completion performance requirements defined respective agreements revenue research development cost reimbursement contracts recognized related costs incurred advance payments received excess amounts earned classified deferred revenue royalty revenue sales ambisome recognized month following corresponding sales occur royalty revenue sales vistide tamiflu recognized received quarter following quarter corresponding sales occur shipping handling costs shipping handling costs incurred inventory purchases product shipments recorded cost goods sold consolidated statements operations research development expenses major components rd expenses consist personnel costs including salaries benefits clinical studies performed contract research organizations cros materials supplies overhead allocations consisting various administrative facilities related costs research development activities also separated three main categories research clinical development gilead sciences inc notes consolidated financial statements continued december organization summary significant accounting policies continued pharmaceutical development research costs typically consist preclinical toxicology work clinical development costs include phase clinical trials well expanded access programs pharmaceutical development costs consist product formulation chemical analysis charge clinical preclinical study costs expense incurred consistent sfas accounting research development costs costs significant component rd expenses clinical preclinical studies performed third party cros accrue costs clinical studies performed cros straightline basis service periods specified contracts adjust estimates required based upon ongoing review level effort actually incurred cro initially estimate work performed contracts occurs ratably service periods expected milestone event total contract completion date expected completion dates estimated based upon terms contracts pastexperience similar contracts monitor levels performance contract including extent patient enrollment activities communications cros adjust estimates required quarterly basis expenses reflect actual effort incurred cro material cro contracts terminable us upon written notice gilead generally liable actual effort expended cro point time contract regardless payment status amounts paid advance services performed refunded contract terminated contracts include additional termination payments become due payable gilead terminates contract additional termination payments recorded expense contract terminated advertising expenses expense costs advertising including promotional expenses incurred advertising expenses million million million stockbased compensation accordance provisions sfas accounting stockbased compensation amended sfas accounting stockbased compensationtransition disclosure sfas elected continue follow accounting principles board opinion apb accounting stock issued employees interpretation fin accounting certain transactions involving stock compensationan interpretation apb opinion accounting employee stock option plans apb exercise price gileads employee director stock options equals exceeds fair value underlying stock date grant compensation expense recognized although elected follow intrinsic value method prescribed apb continue evaluate approach accounting stock options light ongoing industry regulatory developments gilead sciences inc notes consolidated financial statements continued december organization summary significant accounting policies continued table presents combined net income loss basic diluted net income loss per common share compensation cost gilead nexstar pharmaceuticals inc nexstar triangle stock option plans employee stock purchase plan espp determined based estimated fair value awards plans grant purchase date accordance sfas thousands except per share amounts year ended december net income lossas reported add stockbased employee compensation expense included reported net income loss net related tax effects deduct total stockbased employee compensation expense determined fair value based method awards net related tax effects pro forma net income loss net income loss per share basicas reported basicpro forma dilutedas reported dilutedpro forma effect net income loss basic diluted net income loss per common share presented likely representative effects net income loss net income loss per share pursuant sfas future years due subsequent years including additional grants years vesting gilead sciences inc notes consolidated financial statements continued december organization summary significant accounting policies continued fair values awards granted stock option plans espp estimated grant purchase dates using blackscholes option pricing model blackscholes option valuation model developed use estimating fair value traded options vesting restrictions fully transferable addition option valuation models require input highly subjective assumptions including expected stock price volatility employee stock options characteristics significantly different traded options changes subjective input assumptions materially affect fair value estimate managements opinion existing models necessarily provide reliable single measure fair value employee stock options used multiple option approach following assumptions year ended december expected life years vesting date stock options espp discount rate stock options espp volatility expected dividend yield end third quarter fair value stock awards granted determined utilizing volatility rate fourth quarter changed volatility assumption used arrive fair value stock awards recent twoyear time period used purposes calculating expected volatility considering factors stage development length time public company several drug approvals past years enabled us achieve positive cash flow operations believe volatility rate better reflects expected volatility stock going forward volatility used table represents weighted average volatility first three quarters fourth quarter weighted average estimated fair value espp shares purchased per share computations basic diluted net loss per common share computed based weighted average number common shares outstanding period potential common shares convertible notes million shares outstanding stock options warrants million shares excluded computation diluted net loss per share effect would antidilutive basic net income per common share computed based weighted average number common shares outstanding period diluted net income per common share includes effects approximately million stock options include effect million convertible notes would convert approximately million shares gilead sciences inc notes consolidated financial statements continued december organization summary significant accounting policies continued million convertible notes would convert approximately million shares effect assumed conversion antidilutive diluted net income per common share includes effects approximately million stock options warrants include effect million convertible notes would convert approximately million shares effect assumed conversion antidilutive cash cash equivalents consider highly liquid investments insignificant interest rate risk remaining maturity three months less purchase date cash equivalents may enter overnight repurchase agreements purchase securities obligation resell following day securities purchased agreements resell recorded face value reported cash cash equivalents investment policy may enter repurchase agreements repos major banks authorized dealers provided repos collateralized us government securities fair value least fair value securities sold gilead eligible investments investment policy include commercial paper money market funds bank obligations marketable securities determine appropriate classification marketable securities consists solely debt securities time purchase reevaluate designation balance sheet date marketable securities classified availableforsale carried estimated fair values reported either cash equivalents marketable securities december cash cash equivalents include million securities designated availableforsale million december unrealized gains losses availableforsale securities excluded earnings reported separate component stockholders equity interest income includes interest dividends amortization purchase premiums discounts realized gains losses sales securities cost securities sold based specific identification method regularly review investments otherthantemporary declines fair value determine decline fair value investment accounting basis otherthantemporary reduce carrying value securities hold record loss amount decline reductions required past three years concentrations credit risk subject credit risk portfolio cash equivalents marketable securities policy limit amounts invested securities duration industry group investment type issuer except securities issued us government exposed significant concentrations credit risk financial instruments goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return also subject credit risk accounts receivable related product sales significant amount trade accounts receivable arises sales ambisome viread primarily gilead sciences inc notes consolidated financial statements continued december organization summary significant accounting policies continuedsales european subsidiaries export sales distributors europe certain countries payments typically slow primarily greece spain portugal italy accounts receivable balances significant cases slow payment practices reflect pace governmental entities reimburse customers turn may increase financial risk related certain customers sales customers countries tend relatively slow paying past increased future may increase average length time accounts receivable outstanding december past due accounts receivable greece spain portugal italy totaled approximately million approximately million days past due based contractual terms receivables december past due receivables countries million approximately million days past due date experienced significant losses respect collection accounts receivable believe past due accounts receivable reflected consolidated balance sheet including due customers four countries collectible perform credit evaluations customers financial condition generally required collateral many materials utilize operations made one facility example depend single suppliers high quality amphotericin b distearoylphosphatidylcholine high quality cholesterol used manufacture ambisome supplies suppliers interrupted reason may unable ship viread ambisome hepsera emtriva vistide supply products development clinical trials inventories inventories recorded lower cost market cost determined firstin firstout basis periodically review composition inventory order identify obsolete slowmoving otherwise unsaleable items items observed alternate uses inventory record writedown net realizable value period units identified impaired historically inventory writedowns insignificant consistent managements expectations property plant equipment property plant equipment stated cost less accumulated depreciation amortization depreciation amortization recognized using straight line method land depreciated estimated useful lives follows years description estimated useful life buildings improvements laboratory manufacturing equipment office computer equipment leasehold improvements life related lease gilead sciences inc notes consolidated financial statements continued december organization summary significant accounting policies continued office computer equipment includes capitalized computer software capitalized software purchased internally developed computer software leasehold improvements capitalized leased equipment amortized shorter lease term items useful life capitalized interest construction progress included property plant equipment intangible assets intangible assets definite lives amortized estimated useful lives reviewed impairment facts circumstances suggest carrying value assets may recoverable inplace lease intangible asset amortized remaining period related lease term discussed note impairment longlived assets carrying value longlived assets reviewed regular basis existence facts circumstances internally externally may suggest impairment specific potential indicators impairment include significant decrease fair value asset significant change extent manner asset used significant physical change asset significant adverse change legal factors business climate affects value asset adverse action assessment us food drug administration another regulator accumulation costs significantly excess amount originally expected acquire construct asset operating cash flow losses combined history operating cash flow losses projection forecast demonstrates continuing losses associated incomeproducing asset indication impairment test recoverability comparing estimated undiscounted future cash flows expected result use asset eventual disposition carrying amount asset estimating future cash flows assets liabilities grouped lowest level identifiable cash flows largely independent cash flows generated groups undiscounted future cash flows less carrying amount asset impairment loss measured excess carrying value asset fair value recognized cash flow estimates used calculations based managements best estimates using appropriate customary assumptions projections time gilead sciences incnotes consolidated financial statements continued december organization summary significant accounting policies continued foreign currency translation transactions contracts adjustments resulting translating financial statements foreign subsidiaries us dollars excluded determination net income accumulated separate component stockholders equity net foreign exchange transaction gains losses reported selling general administrative expenses consolidated statements operations realized gains losses million million million hedge certain foreign currency exposures related outstanding trade accounts receivable firmly committed purchase transactions forecasted product sales foreign exchange forward contracts general contracts expose us market risk gains losses contracts offset gains losses transactions hedged exposure credit risk contracts function changes interest currency exchange rates therefore varies time gilead limits risk counterparties contracts may unable perform transacting major us banks also limit risk loss entering contracts provide net settlement maturity therefore overall risk loss event counterparty default limited amount unrecognized unrealized gains outstanding contracts ie contracts positive fair value date default enter speculative foreign currency transactions write options presently hedge net investment foreign subsidiaries accounting hedges accounts receivable record changes fair value selling general administrative expense derivative instruments designated hedges sfas selectively hedge anticipated currency exposures purchasing forward contracts hedge firmly committed purchases transactions anticipated product sales next year less designated cash flow hedges sfas unrealized gains losses underlying forward contracts recorded comprehensive income recognized earnings forecasted transaction occurs december december net unrealized losses open foreign exchange forward contracts million million respectively losses revenue hedges reduced product sales million million notional amounts forward exchange contracts outstanding million december million december contracts maturities one year less see note discussion derivative financial instruments adoption sfas fair value financial instruments companys financial instruments consist principally cash cash equivalents marketable securities accounts receivable certain noncurrent assets forward foreign exchange contracts accounts payable longterm obligations convertible notes cash cash equivalents marketable securities forward foreign exchange contracts hedge accounts receivable reported respective fair values balance sheet forward foreign exchange contracts hedge firmly committed purchases sales recorded fair value net related deferred gain loss resulting reported net balance zero fair value convertible senior notes december gilead sciences inc notes consolidated financial statements continued december organization summary significant accounting policies continued million fair value december million carrying value end period million fair value convertible subordinated notes december million carrying value million gilead called convertible subordinated notes redemption november converted gilead common stock december fair values december december convertible notes determined obtaining quotes market maker notes believe remaining financial instruments reported consolidated balance sheet amounts approximate current fair values recent accounting pronouncements january fasb issued fasb interpretation fin consolidation variable interest entities interpretation arb fin requires certain variable interest entities consolidated primary beneficiary entity equity investors entity characteristics controlling financial interest sufficient equity risk entity finance activities without additional subordinated financial support parties fin effective immediately new variable interest entities created acquired january create acquire new variable interest entities january variable interest entities created acquired prior february provisions fin amended must applied end first interim annual period ending march adoption fin material impact consolidated financial statements derivative financial instruments january gilead adopted sfas standard requires gilead recognize derivatives either assets liabilities measured fair value enter foreign currency forward contracts hedge changes fair value monetary assets liabilities denominated nonfunctional currency derivative designated meets definition fair value hedge changes fair value derivative hedged item attributable hedged risk recognized earnings company enters foreign currency forward contracts generally maturities months less hedge future cash flows related purchase transactions forecasted product sales foreign denominated currencies derivative instruments employed eliminate minimize certain foreign currency exposures confidently identified quantified accordance sfas hedges related anticipated foreign currency purchases raw materials forecasted product sales designated documented inception respective hedge designated cash flow hedges evaluated effectiveness quarterly terms forward contract underlying transaction matched inception forward contract effectiveness calculated comparing fair value contract change forward value underlying hedged item effective component hedge recorded accumulated comprehensive income substantially values reported accumulated comprehensive income december reclassified toearnings within months residual changes fair value instruments ineffectiveness gilead sciences inc notes consolidated financial statements continued december derivative financial instruments continued recognized immediately selling general administrative expense ineffectiveness significant result entering collaborations prior years gilead holds warrants purchase stock two nonpublic companies one completed initial public offering january see note warrants net exercise features sfas classified derivative instruments upon adoption gilead recorded fair value one warrants million offsetting adjustment cumulative change accounting principle million loss hedging contracts recognized consolidated income statement million decrease fair value derivatives recognized accumulated comprehensive income december fair value derivatives included accumulated comprehensive income material acquisition triangle pharmaceuticals inc january completed acquisition net assets triangle expand antiviral pipeline triangle development stage company particular focus potential therapies hiv including aids hepatitis b virus hbv triangles portfolio consisted several drug candidates clinical trials including emtriva emtricitabine treatment hiv infection emtricitabine treatment chronic hepatitis b amdoxovir treatment hiv infection clevudine treatment chronic hepatitis b july us food drug administration fda approved marketing emtriva treatment hiv october european commission granted marketing authorisation emtriva fifteen member states european union triangle acquisition accounted acquisition assets rather business combination accordance criteria outlined emerging issues task force triangle development stage company commenced planned principal operations lacked necessary elements business completed products therefore ability access customers results operations triangle since january included consolidated financial statements primarily consist research development expenses lesser extent selling general administrative expenses december part arrangements contemplated proposed acquisition triangle gilead million loan extended triangle working capital corporate purposes triangle issued gilead unsecured convertible promissory note upon completion acquisition january loan eliminated consolidated financial statements aggregate purchase price million including cash paid million outstanding stock fair value stock options assumed million estimated direct transaction costs million employee related costs million part purchase established workforce reduction plan also assumed obligations various change control agreements acquisition date approximately million employee termination costs change control obligations recorded liability paid gilead sciences inc notes consolidated financial statements continued december acquisition triangle pharmaceuticals inc continued period approximately two years december approximately million remained liability following table summarizes purchase price allocation january thousands net tangible assets assembled workforce deferred compensation inprocess research development million net tangible assets includes assumed liabilities million million value assigned assembled workforce amortized three years estimated useful life asset deferred compensation represents intrinsic value unvested stock options assumed transaction amortized remaining vesting period options extends january upon reversal deferred tax asset valuation allowance fourth quarter remaining million assembled workforce asset eliminated see note gilead sciences inc notes consolidated financial statements continued december acquisition triangle pharmaceuticals inc continued approximately million purchase price allocated inprocess research development represented fair value triangles incomplete research development programs yet reached technological feasibility alternative future use acquisition date summary programs acquisition date updated subsequent developments follows value program description status development millions emtricitabine nucleoside analogue four phase studies completed us hivsingle shown marketing approval received agent inhibitor hiv replication fda july european union patients approval received european commission october emtricitabine potential coformulation acquisition date work tenofovir df tenofovir emtricitabine yet commenced potential co fixed dose formulation except extent work combination emtricitabine single agent hiv therapy progressing since successfully completed coformulating tenofovir emtricitabine single pill completed three stability studies bioequivalence study required approval amdoxovir hiv purine dioxolane phase trials acquisition date nucleoside may offer effective january announced advantages intent terminate licensing marketed nucleosides agreement emory university activity university georgia research drug resistant viruses foundation inc development exhibited patients hiv discontinued infection clevudine hbv pyrimidine nucleoside phase trials acquisition date analogue effective august licensing shown inhibitor agreement bukwang pharm ind co hbv replication patients ltd terminated development chronically infected discontinued hbv emtricitabine inhibitor hbv phase trial ongoing hbv replication patients chronically infected hbv gilead sciences inc notes consolidated financial statements continued december acquisition triangle pharmaceuticals inc continued remaining efforts completion triangles research development projects primarily consist clinical trials cost length success extremely difficult predict numerous risks uncertainties exist could prevent completion development including ability enroll patients clinical trials possibility unfavorable results clinical trials risk failing obtain fda regulatory body approvals feedback regulatory authorities results clinical trials might require modifications delays later stage clinical trials additional trials performed certain emtricitabine treatment chronic hepatitis b purchased triangle approved us european union whether marketing approvals significant limitations use terminated rights respect potential products acquired acquisition triangle also yet approval fixeddose combination product containing tenofovir df emtricitabine future discussions regulatory agencies determine amount data needed timelines review may differ materially current projections acquired products development may never successfully commercialized emtriva example product many similarities existing products result may difficult successfully penetrate market achieve significant revenues addition emtricitabine treatment chronic hepatitis b faces significant uncertainties associated pricing efficacy cost produce may successfully resolved result may make strategic decision discontinue development product clevudine amdoxovir believe commercialization difficult relative opportunities pipeline programs completed timely basis prospects future revenue growth would adversely impacted value acquired inprocess research development determined estimating related future net cash flows using present value risk adjusted discount rate discount rate significant assumption based estimated weighted average cost capital adjusted upward risks associated projects acquired projected cash flows acquired projects based estimates revenues operating profits related projects considering stage development potential product acquired time resources needed complete thedevelopment approval product life potential commercialized product associated risks including inherent difficulties uncertainties developing drug compound including obtaining fda regulatory approvals risks related viability potential alternative treatments future target markets acquisition real estate september completed purchase foster city campus approximately million cash purchase included buildings totaling square feet office laboratory space lakeside drive foster city california accordance sfas business combinations sfas goodwill intangible assets purchase price allocated land buildings existing inplace leases based estimated relative fair values land buildings recorded million gilead sciences inc notes consolidated financial statements continued december acquisition real estate continued million respectively fair value buildings depreciated remaining economic life estimated years used market approach value existing leases acquired recorded intangible asset approximately million amortized straightline basis net rental income approximately two years remaining term leases net rental income generate leases amortization intangible asset included interest income net approximately million year ended december accumulated amortization intangible asset million december asset impairment recorded asset impairment charge million certain longlived assets primarily leasehold improvements manufacturing laboratory equipment classified held use noncash charge driven decision terminate liposomal research development activities san dimas discontinue daunoxome product line impairment based analysis undiscounted cash flows generated affected assets compared carrying value carrying value exceeded related undiscounted cash flows wrote carrying value longlived assets fair value accordance sfas accounting impairment disposal longlived assets fair value derived using expected cash flow approach sale oncology assets december gilead completed sale oncology assets pipeline clinical candidates oncology related intellectual property well boulder colorado operations including clinical research drug development operations infrastructure facilities osi three clinical development candidates sold osi nx liposomal lurtotecan gs nucleoside analogue gs l liposomal thymidylate synthase inhibitor consideration gilead received million cash shares osi common stock valued approximately million december number shares issued gilead determined dividing million average closing sale price osi common stock days preceding december also entitled additional payments osi million either cash combination cash osi common stock osi reaches certain development milestones nx advanced oncology product candidates sold osi milestone payments received osi recognized contract revenues upon receipt based upon december net book value oncology assets sold million transaction costs million million related acceleration approximately options purchase gilead common stock realized pretax gain million fourth quarter carrying value transferred assets relates primarily certain property equipment osi assumed gileads oncologyrelated clinical preclinical obligations well various lease obligations related manufacturing agreement produce osi liposomal formulations nx gs l two liposomal products sold osi manufacturing facility san dimas ca gilead sciences inc notes consolidated financial statements continued december sale marketable securities july gilead sold remaining shares osi common stock approximately million shares partial consideration sale oncology assets osi december time recorded fair market value approximately million connection sale remaining shares recognized nonoperating loss approximately million reflected consolidated results operations year ended december availableforsale securities following summary availableforsale securities estimated fair values availableforsale securities based prices obtained commercial pricing services thousands gross gross unrealized unrealized estimated cost gains losses fair value december us treasury securities obligations us government agencies corporate debt securities assetbacked securities debt securities total december us treasury securities obligations us government agencies corporate debt securities assetbacked securities debt securities total debt securities consist primarily money market funds also maintain marketable securities nominal value recorded noncurrent assets december december securities net unrealized loss approximately million million respectively following table presents certain information related sales availableforsale securities thousands year ended december proceeds sales gross realized gains sales gross realized losses sales gilead sciences inc notes consolidated financial statements continued december availableforsale securities continued december million portfolio marketable securities excludes million assetbacked securities contractual maturity less one year million portfolio contractual maturity greater one year less three years none estimated maturities assetbacked securities exceed three years balance sheet detail thousands december inventories raw materials work process finished goods total property plant equipment net buildings improvements including leasehold improvements laboratory manufacturing equipment office computer equipment capitalized leased equipment construction progress less accumulated depreciation amortization subtotal land total accrued compensation employee benefits accrued bonuses accrued compensation employee benefits total accrued liabilities accrued medicaid rebates fair value forward currency contracts income taxes payable accrued sales marketing expenses liabilities total gilead sciences inc notes consolidated financial statements continued december collaborative arrangements contracts chiron corporation august entered nonexclusive licensing agreement chiron corporation chiron research development commercialization small molecule therapeutics selected hepatitis c virus hcv drug targets agreement gilead received nonexclusive rights use chirons hcv technology develop commercialize products treatment hcv terms agreement paid chiron upfront license fee recorded research development expense future alternative use technology also agreed make additional payments chiron certain clinical regulatory milestones met royalty payments event product developed using licensed technology japan tobacco inc july gilead entered licensing agreement japan tobacco inc japan tobacco japan tobacco commercialize products hiv portfolio japan agreement includes viread emtriva future coformulation two products terms agreement received front fee entitled receive additional cash payments upon achievement certain milestones japan tobacco also pay us royalty net sales products japan upfront fee recorded deferred revenue amortized contract revenue period remaining obligations agreement approximately years emory university april triangle obtained january acquired part acquisition triangle exclusive worldwide license emory universitys rights purified forms emtricitabine use hiv hepatitis b fields obligated make certain milestone royalty payments emory including annual minimum royalties beginning third year first fda registration granted antihiv product incorporating emtricitabine technology us third year first registration granted antihepatitis b product incorporating emtricitabine technology certain major market countries hiv hepatitis b indications respectively triangle began paying license maintenance fees development milestones yet achieved license agreement emory terminates upon later patent expiration expiration obligation pay royalties addition right terminate agreement entirety respect one indications hiv hbv one countries prior expiration time upon days notice glaxosmithkline april gilead gsk entered licensing agreement providing gsk rights commercialize hepsera antiviral treatment chronic hepatitis b asia latin america certain territories agreement retained rights hepsera u canada eastern western europe australia new zealand gsk received exclusive rights develop hepsera solely gilead sciences inc notes consolidated financial statements continued december collaborative arrangements contracts continued treatment chronic hepatitis b territories significant include china korea japan taiwan addition gsk paid us front licensing fee million first payment additional obligations may pay million upon achievement gsk certain regulatory development commercial milestones million million received us approval hepsera september million received canadian approval hepsera august gsk also pay us royalty net sales hepsera gsk territories gsk full responsibility development commercialization hepsera gsks territories million upfront fee million approval fees recorded deferred revenue total million million recognized contract revenue respectively million balance deferred revenue december amortized contract revenue period remaining obligations agreement approximately years december gilead entered agreement glaxo wellcome gsk giving gilead rights gs l novel antitumor compound gilead developing gs l liposome evaluating preclinical studies agreement gilead exclusive worldwide rights develop commercialize gs l indications malaria gilead paid gsk upfront fee included rd expense december compound assigned osi part sale oncology assets may gilead entered threepart collaboration gsk gsk received nonexclusive right use gileads proprietary selex process target validation b gilead received exclusive rights subject gsks right elect participate activities develop commercialize nx liposomal formulation gsks proprietary topoisomerase inhibitor lurtotecan c gsk acquired shares gilead common stock million private offering december collaboration license agreement modified revised terms agreement gsk waived right participate development commercialization nx right receive royalties giving gilead exclusive rights compound december compound also assigned osi part sale oncology assets cubist pharmaceuticals september gilead cubist pharmaceuticals jointly announced termination licensing agreement commercialization cidecin daptomycin injection oral formulation daptomycin agreement executed january granted gilead exclusive commercialization rights products european countries following regulatory approval terms termination agreement gilead owe future payments cubist cubist reacquired european rights products upon termination million recorded research development expense represented remaining unamortized asset related preclinical oral formulation daptomycin gilead sciences inc notes consolidated financial statements continued december collaborative arrangements contracts continued archemix october entered agreement archemix corporation relating selex technology agreement archemix obtained exclusive rights selex process including therapeutic commercial applications extent already licensed preexisting agreements archemix paid us million million required license agreement license equity holdings inc ulehi paid receipts ulehi therefore recognized million million revenue respectively also received warrant purchase shares archemix common stock value material required license agreement ulehi transferred warrant time since transferred remainder warrant ulehi additional payments due archemix agreement eyetech march entered agreement eyetech pharmaceuticals inc relating proprietary aptamer eye known macugen currently phase clinical trials macugen inhibitor vascular endothelial growth factor vegf known play role development certain ophthalmic diseases terms agreement eyetech received worldwide rights therapeutic uses macugen product successfully commercialized eyetech pay us royalties worldwide sales product eyetech also responsible research development costs provided clinical supplies product eyetech march also received million upfront licensing fee eyetech april recognized revenue ratably oneyear supply agreement period accordingly million license fee recorded contract revenue agreement remainder license fee recognized revenue also entitled additional cash payments eyetech million eyetech reaches certain macugen development milestones additionally received warrant purchase shares eyetech series b convertible preferred stock exercisable price per share price stock issued investors see note description accounting treatment warrant fujisawa rights market ambisome subject agreement gilead fujisawa healthcare inc successor fujisawa usa inc fujisawa terms fujisawa agreement amended fujisawa gilead copromote ambisome us fujisawa sole marketing rights ambisome canada exclusive marketing rights ambisome rest world provided pay royalties fujisawa connection sales significant asian markets including japan connection us sales fujisawa purchases ambisome gilead cost sales canada fujisawa purchases ambisome cost plus specified percentage fujisawa collects payments sale ambisome us canada receive fujisawas gross profits sale ambisome us gross profits include deduction cost goods sold giving us current effective royalty rate approximately fujisawas net sales ambisome gilead sciences inc notes consolidated financial statements continued december collaborative arrangements contracts continued us connection agreement us fujisawa recorded royalty revenue million million million sumitomo september gilead sumitomo entered agreement pursuant sumitomo agreed develop market ambisome japan terms agreement sumitomo paid us initial million licensing fee less withholding taxes million october million milestone payment less withholding taxes million march sumitomo also required make additional payments us certain clinical commercial milestones met pay us royalties japanese ambisome sales agreement gilead obligated provide certain quantity ambisome sumitomo charge ambisome yet approved marketing japan roche september gilead entered collaboration agreement roche develop commercialize therapies treat prevent viral influenza roche agreement roche agreement roche received exclusive worldwide rights gileads proprietary influenza neuraminidase inhibitors prior roche made license fee developmental milestone payments totaling million gilead recognized million contract revenue milestone payments roche related tamiflu milestones achieved year milestones included filing regulatory approval japan treatment influenza japanese approval application filing us regulatory approval prevention influenza receipt approval us recognized million milestone payment filing application market tamiflu prophylaxis european union recognized million milestone payments european approval tamiflu treatment prophylaxis december gilead entitled additional cash payments roche million upon roche achieving additional developmental regulatory milestones addition roche required pay gilead royalties net product sales gilead began receiving royalties roches sales tamiflu first quarter recorded total million tamiflu royalties million royalties million royalties recognize royalty revenue roche quarter following quarter related tamiflu sales occur pfizerin august gilead pfizer formerly pharmacia corporation entered license supply agreement pfizer agreement market vistide countries outside us terms pfizer agreement pfizer paid gilead initial license fee million subsequent cumulative effect change accounting principle recorded effective first quarter gilead recognizing initial license fee straightline basis supply arrangement period sixteen years agreement date net impact change accounting principle pfizer agreement increase net loss million gilead sciences inc notes consolidated financial statements continued december collaborative arrangements contracts continued cumulative effect change accounting principle related initial license fee pfizer million charge results operations additional contract revenue million recognized subsequent accounting change remaining million related deferred revenue expected recognized straightline basis contract revenue remaining supply period terms pfizer agreement related agreements covering expanded access programs vistide outside us gilead responsible maintaining cidofovir patent portfolio supplying pfizer bulk cidofovir used manufacture finished vistide product gilead entitled receive royalty based upon pfizers sales vistide gilead receives portion royalty upon shipping either bulk drug substance vistide pfizer remainder upon pfizers sale vistide third parties royalties gilead receives product sold third parties recorded deferred revenue thirdparty sales occur december recorded balance sheet approximately million deferred revenue million december recognized royalty revenue sales vistide outside united states pharmacia million million million iocbrega gilead entered agreements institute organic chemistry biochemistry academy sciences czech republic rega stichting iocbrega relating certain nucleotide compounds discovered two institutions agreements gilead received exclusive right manufacture use sell nucleotide compounds gilead obligated pay iocbrega percentage net revenues received sales products containing compounds subject minimum royalty payments products covered agreement include vistide hepsera viread exclude tamiflu gilead currently makes quarterly payments iocbrega based percentage vistide hepsera viread sales december agreements iocbrega amended provide reduced royalty rate future sales hepsera viread return front payment gilead million upon signing agreement payment recorded longterm prepaid royalty classified noncurrent assets balance sheet december recognized royalty expense expected commercial life viread hepsera amortization million payment began product launch dates viread hepsera totaled million december southern research institute december gilead entered agreement southern research institute giving gilead worldwide rights develop commercialize gs antitumor compound gilead evaluating preclinical studies terms agreement gilead paid southern research institute upfront fee included research development expense december compound assigned osi part sale oncology assets gilead sciences inc notes consolidated financial statements continued december investment sale unconsolidated affiliate july established proligo llc delaware limited liability company proligo wholly owned subsidiary transferred assets nexstar technology products division proligo august sold interest interest proligo third party payment interest received million cash interest perseptive biosystems gmbh company hamburg germany specializes manufacture nucleoside phosphoramidite monomers prior february made two additional cash investments proligo total million maintain ownership interest proligo accounted investment proligo using equity method accounting gilead sold interest proligo degussa corporation million cash proceeds net gileads investment proligo reflected million gain sale unconsolidated affiliate prior date sale gilead recorded million equity loss proligo longterm obligations longterm obligations consist following thousands december capital lease obligations monthly installments interest rates ranging fixed rate debt monthly installments secured equipment interest rates ranging total longterm obligations less current portion longterm obligations due one year future minimum lease payments capital lease obligations follows thousands year ending december less amount representing interest total terms various agreements require us comply certain financial operating covenants december compliance covenants gilead sciences inc notes consolidated financial statements continued december convertible notes december gilead issued million convertible senior notes due december private offering goldman sachs co resold notes qualified institutional investors notes convertible total shares gilead common stock per share conversion price higher gileads common stock price notes issuance date notes redeemable whole part option gilead time june specified redemption prices plus accrued interest debt issuance costs million incurred connection issuance notes recorded noncurrent assets amortized interest expense straightline basis contractual term notes december gilead issued million convertible subordinated notes due december private offering jp morgan co lehman brothers morgan stanley dean witter resold notes private institutional investors notes convertible total shares gilead common stock per share conversion price higher gileads common stock price notes issuance date notes redeemable whole part option gilead time december specified redemption prices plus accrued interest debt issuance costs million incurred connection issuance thenotes recorded noncurrent assets amortized interest expense straightline basis contractual term notes november gilead called convertible subordinated notes redemption converted shares common stock december upon conversion million remaining balance related debt issuance costs reclassified additional paid capital commitments contingencies lease arrangements entered various longterm noncancelable operating leases equipment facilities facility leases san dimas california durham north carolina expire various dates one san dimas leases contains two fiveyear renewal options durham lease two sevenyear renewal options also operating leases sales marketing administrative facilities europe australia various terms equipment leases include corporate airplane initial term two years annual renewal option ten years lease expense net sublease income operating leases totaled approximately million million million gilead sciences inc notes consolidated financial statements continued december commitments contingencies continued aggregate noncancelable future minimum rental payments operating leases net aggregate future minimum rentals received us noncancelable subleases follows thousands operating leases net years ending december noncancelable subleases thereafter future minimum rental receipts due us noncancelable subleases million million million legal proceedings reached settlement elan corporation plc elan successor company liposome company companies agreed dismiss legal proceedings involving ambisome gileads liposomal formulation amphotericin b terms initial settlement agreement made initial payment elan million agreed make additional royalty payments based ambisome sales recorded million accounting charge accrued litigation settlement expenses representing estimated net present value future minimum payments required make june elan gilead entered agreement terminating remaining ambisome payment obligations initial settlement agreement exchange payment elan million excess million settlement amount remaining accrued litigation settlement expenses balance million amortized remaining life patents approximately four years september gilead entered settlement agreement release university license equity holdings inc ulehi archemix corporation concerning rights identify aptamers using selex technology licensed ulehi gilead settlement agreement release resolves disputes among parties arising gileads assignment rights identify certain aptamers archemix september county westchester new york westchester served gilead complaint alleges gilead large number pharmaceutical manufacturer defendants report prices products overstate average wholesale price awp allegedly inflating reimbursement rates medicaid program causing westchester pay artificially inflated prices covered drugs including case gilead viread addition westchester argues defendants including gilead accurately report best price medicaid program complaint asserts varying claims federal rico statutes state law corollaries well state law claims deceptive trade practices common law fraud gilead intends vigorously defend gilead sciences inc notes consolidated financial statements continued december commitments contingencies continued allegations complaint seeks undetermined amount damages well relief including declaratory injunctive relief defendants lawsuit named numerous lawsuits comparable awp allegations knowledge gilead named lawsuits gilead named served lawsuits comparable awp allegations adverse results could result material damages purported class action complaint filed november united states district court northern district california gilead companys chief executive officer chief financial officer executive vice presidents operations research development senior vice presidents manufacturing research complaint alleges defendants violated federal securities laws specifically sections b securities exchange act rule b securities exchange commission making certain alleged false misleading statements plaintiff seeks unspecified damages behalf purported class purchasers gileads securities period july october similar actions subsequently filed court issued order consolidating lawsuits single action december believe meritorious defenses allegations contained complaint intend defend case vigorously trial date scheduled february court issued order appointing lead plaintiffs action lead plaintiffs march file consolidated complaint december two purported shareholder derivative lawsuits filed individual shareholders behalf gilead directors certain executive officers superior court state california county san mateo alleging among things defendants violated california corporations code breached fiduciary duties owing gilead gilead named nominal defendant plaintiffs seek unspecified damages behalf gilead connection alleged insider trading period july october defendants alleged breach fiduciary duties abuse control waste mismanagement two cases consolidated single action january plaintiffs filed consolidated complaint february trial date scheduled intend take appropriate action defend interests connection litigation also party various legal actions arose ordinary course business believe legal actions material adverse impact business results operations financial position stockholders equity preferred stock gilead shares authorized preferred stock issuable series board directors board authorized determine designation powers preferences rights series reserved shares preferred stock potential issuance preferred share purchase rights plan preferred stock outstanding december december gilead sciences inc notes consolidated financial statements continued december stockholders equity continued employee stock purchase plan gileads employee stock purchase plan espp employees purchase shares gilead common stock based percentage compensation purchase price per share must equal least lower percent market value date offered date purchased total million shares ofcommon stock reserved issuance espp december million shares total shares reserved issued espp million shares december stock option plans december gilead adopted incentive stock option plan supplemental stock option plan issuance common stock employees consultants scientific advisors april board approved granting certain additional nonqualified stock options terms conditions substantially similar granted supplemental stock option plan none options issued plans described exercise prices less fair value underlying stock date grant options vest five years pursuant formula determined board expire ten years shares available grant future options plans november gilead adopted stock option plan plan issuance common stock employees consultants options issued plan shall discretion board either incentive stock options nonqualified stock options may plan amended exercise price stock options must least equal fair value gileads common stock date grant options vest five years pursuant formula determined board expire ten years plan amended restated april extend term plan may stockholders approved amendment plan increased total number authorized shares plan december shares available grant future options plan november gilead adopted nonemployee directors stock option plan directors plan issuance common stock nonemployee directors pursuant predetermined formula exercise price options granted directors plan must least equal fair value gileads common stock date grant options granted january vesting five years date grant quarterly five percent installments initial options granted january new directors vest three years date grant equal annual installments annual grants thereafter existing directors vest months options expire ten years may stockholders approved amendment directors plan increased total number authorized shares plan december shares available grant future options directors plan stock plans assumed gilead merger nexstar include stock option plan plan incentive stock plan director option plan collectively nexstar plans options pursuant nexstar plans issued outstanding july gilead sciences inc notes consolidated financial statements continued december stockholders equity continued converted options purchase gilead common stock result merger remain subject original terms conditions shares available grant future options nexstar plans nexstars plan allows certain option holders execute cashless exercises options cashless exercise transaction option holder specifies many shares exercised gilead issues specified number shares less number would required cover exercise price based fair value stock exercise date several option holders performed cashless exercises result option awards considered variable therefore recognized nominal amount compensation expense million july options outstanding category stock plans assumed gilead acquisition net assets triangle include stock option plan separate plan chief executive officer triangle collectively triangle plans options pursuant plan issued outstanding january converted options purchase approximately million shares gilead common stock result acquisition remain subject original terms conditions shares available grant future options either triangle plans following table summarizes activity gilead nexstar triangle stock option plans three years period ended december option grants presented table exercise prices less fair value underlying stock grant date shares thousands year ended december weighted weighted weighted average average average exercise exercise exercise shares price shares price shares price outstanding beginning year granted assumed forfeited exercised outstanding end year exercisable end year weighted average fair value options granted gilead sciences inc notes consolidated financial statements continued december stockholders equity continued following summary gilead options outstanding options exercisable december options thousands options outstanding options exercisable weighted average weighted remaining average weighted options contractual exercise options average range exercise prices outstanding life years price exercisable exercise price total company reserved aggregate million shares common stock future issuance equity compensation plans december including million issuable espp million issuable stock option plans approximately million shares reserved issuance senior convertible notes preferred share purchase rights plan november adopted preferred share purchase rights plan rights plan plan provides distribution preferred stock purchase right dividend share gilead common stock purchase rights currently exercisable certain conditions involving acquisition proposed acquisition person group common stock purchase rights permit holders holder purchase gilead common stock discount market price time upon payment specified exercise price per purchase right addition event certain business combinations purchase rights permit purchase common stock acquirer discount market price time certain conditions purchase rights may redeemed board whole part price per purchase right purchase rights voting privileges attached automatically trade gilead common stock october october board directors approved amendments rights plan first amendment provided among things increase exercise price right plan extension term plan november october second amendment provides among things increase exercise price right plan adjusting two stock splits extension term rights plan october acceleration stock options december completed sale oncology assets osi part transaction accelerated approximately options purchase gilead common stock value million see note discussion gilead sciences inc notes consolidated financial statements continued december comprehensive income loss following reclassification adjustments required avoid doublecounting net realized gains losses sales securities previously included comprehensive income loss prior sales securities thousands year ended december net gain loss sales securities comprehensive income net unrealized gain loss arising year reclassification adjustment net unrealized gain loss reported comprehensive income loss balance accumulated comprehensive income reported balance sheet consists following components thousands december net unrealized gain loss availableforsale securities net unrealized gain loss cash flow hedges net foreign currency translation gain loss accumulated comprehensive income disclosures segments enterprise related information sfas disclosures segments enterprise related information sfas establishes standards way public business enterprises report information operating segments annual financial statements requires enterprises report selected information operating segments interim financial reports sfas also establishes standards related disclosures products services geographic areas major customers company operates one business segment primarily focuses development commercialization human therapeutics infectious diseases products aggregated one segment majority products viread ambisome accounted sales similar economic characteristics similarities including nature products production processes type customers distribution methods regulatory environment company derives revenues primarily product sales viread ambisome well royalty contract revenue royalty revenue relatesprimarily sales ambisome fujisawa well sales tamiflu roche contract revenue relates licensing selex process patent estate archemix milestone payments roche related development tamiflu license milestone payments gsk related development hepsera license fees eyetech rights aptamer eye currently known macugen gilead sciences inc notes consolidated financial statements continued december disclosures segments enterprise related information continued product sales consist following thousands year ended december viread ambisome following table summarizes revenues external customers collaborative partners geographic region revenues attributed countries based location customer collaborative partner thousands year ended december united states united kingdom france spain germany italy switzerland european countries countries consolidated total revenues december net book value property plant equipment million approximately assets located us december net book value property plant equipment million approximately assets located us product sales three distributors accounted approximately total revenues product sales three distributors accounted approximately total revenues product sales one distributor exceed total revenues total revenues fujisawa included product sales royalties approximately total revenues gilead sciences inc notes consolidated financial statements continued december income taxes provision income taxes consisted following thousands year ended december federal current deferred state current deferred foreign current deferred foreign pretax loss million million million companys foreign subsidiaries generated operating losses reflecting costs building commercial infrastructure europe foreign subsidiaries investment companys research development effortsthe difference provision taxes income amount computed applying federal statutory income tax rate income loss provision income taxes equity loss unconsolidated affiliate cumulative effect change accounting principle explained thousands year ended december income loss provision income taxes equity loss unconsolidated affiliate cumulative effect change accounting principle tax federal statutory rate previously unbenefitted net operating losses state taxes net federal benefit federal alternative minimum taxes reversal valuation allowance purchased inprocess research development foreign losses different rates foreign earnings different rates gilead sciences inc notes consolidated financial statements continued december income taxes continued tax benefits associated stock option exercises employee stock purchase plan resulted cumulative tax benefit million year ended december benefit credited additional paidin capital realized deferred income taxes reflect net tax effects temporary differences carrying amounts assets liabilities financial reporting purposes amounts used income tax purposes significant components deferred tax assets liabilities december follows thousands december net operating loss carryforwards research credits capitalized research development expenses reserves accruals currently deductible net total deferred tax assets valuation allowance net deferred tax assets recognized valuation allowance decreased million year ended december increased million year ended december december based upon level historical taxable income projections future taxable income periods deferred tax assets deductible determined likely certain deferred tax assets realized therefore released related valuation allowance reversal valuation allowance resulted realization income tax benefits approximately million deferred tax asset attributable net operating loss carryforwards included tax benefits million related exercise employee stock options benefits recorded directly additional paid capital reversal valuation allowance also resulted reduction remaining assembled workforce asset million established upon acquisition triangle december remaining valuation allowance million net deferred tax asset concluded based standard set forth sfas accounting income taxes likely realize benefits related deferred tax assets assess need valuation allowance quarter end based available evidence approximately million valuation allowance december relates tax benefits stock option deductions credited additional paidin capital realized december us federal net operating loss carryforwards approximately million state net operating loss carryforwards approximately million federal net operating loss carryforwards expire various dates beginning utilized state net operating loss carryforwards expire various dates gilead sciences inc notes consolidated financial statements continued december income taxes continued utilized addition federal state tax credit carryforwards approximately million million respectively expire years utilization net operating losses credits may subject annual limitation due ownership change limitations provided internal revenue codeand similar state provisions annual limitation may result expiration net operating losses credits utilization retirement savings plan december gilead maintains one retirement savings plan eligible employees may defer compensation income tax purposes section k internal revenue code prior january gilead maintained two separate retirement savings plans one plan primarily covered former nexstar employees nexstar plan plan primarily covered gileads remaining eligible employees gilead plan december approximately million representing shares gilead common stock held nexstar plan trust plan participants effective january nexstar plan terminated combined gilead plan shares gilead common stock held nexstar plan subsequently liquidated proceeds deposited various investment options available gilead plan gilead plan employees may contribute eligible annual compensation effective january gilead began making matching contributions gilead plan contribute employees first contributions annual maximum match total matching contribution gilead plan million million million quarterly results unaudited following table thousands except per share amounts st quarter nd quarter rd quarter th quarter total revenues gross profit product sales total costs expenses net income loss net income loss per common sharebasic net income loss per common sharediluted gilead sciences inc notes consolidated financial statements continued december quarterly results unaudited continued st quarter nd quarter rd quarter th quarter total revenues gross profit product sales total costs expenses net income loss net income loss per common sharebasic net income loss per common sharediluted first quarter gilead completed acquisition net assets triangle recorded charge million inprocess research development third quarter gilead reimbursed million research development expenses resulting settlement contractual dispute vendor fourth quarter gilead recorded noncash impairment charges certain longlived assets million million related asset writedowns addition recorded income tax benefit million related reduction valuation allowance certain net deferred tax assets third quarter gilead realized million nonoperating loss upon sale remaining shares osi pharmaceuticals inc gilead sciences inc schedule ii valuation qualifying accounts balance additions balance beginning charged charged end period expense deductions period year ended december allowance doubtful accounts allowance sales returns valuation allowance deferred tax assets year ended december allowance doubtful accounts allowance sales returns valuation allowance deferred tax assets year ended december allowance doubtful accounts allowance sales returns valuation allowance deferred tax assets charged current tax expense additional paid capital charged deferred tax benefit charged current tax expense